Rho kinase inhibitors

ABSTRACT

Disclosed are novel substituted 2H-isoquinolin-1-one and 3H-quinazolin-4-one derivatives useful as inhibitors of Rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of Rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.

RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.15/142,448 filed Apr. 29, 2016, which is a continuation of U.S. patentapplication Ser. No. 14/754,787 filed Jun. 30, 2015, which is acontinuation of U.S. patent application Ser. No. 14/461,597, filed Aug.18, 2014, which is a divisional of U.S. patent application Ser. No.11/856,740, filed Sep. 18, 2007, now U.S. Pat. No. 8,809,326 issued Aug.19, 2014, which claims priority to U.S. Provisional Patent ApplicationNo. 60/864,484, filed Nov. 6, 2006, and U.S. Provisional PatentApplication No. 60/826,284, filed Sep. 20, 2006, each of which isincorporated herein by reference in its entirety.

FIELD OF THE INVENTION

This invention relates to substituted 2H-isoquinolin-1-one and3H-quinazolin-4-one derivatives which are useful as inhibitors of Rhokinase and are thus useful for treating a variety of diseases anddisorders that are mediated or sustained through the activity of Rhokinase, including cardiovascular diseases, cancer, neurologicaldiseases, renal diseases, bronchial asthma, erectile dysfunction, andglaucoma. This invention also relates to pharmaceutical compositionscomprising these compounds, methods of using these compounds in thetreatment of various diseases and disorders, processes for preparingthese compounds and intermediates useful in these processes.

BACKGROUND

Rho-Kinase (ROCK) is a member of the serine-threonine protein kinasefamily. ROCK exists in two isoforms, ROCK1 and ROCK2 (T. Ishizaki etal., EMBO J., 1996, 15, 1885-1893). ROCK has been identified as aneffector molecule of RhoA, a small GTP-binding protein (G protein) thatplays a key role in multiple cellular signaling pathways. ROCK and RhoAare ubiquitously expressed across tissues. The RhoA/ROCK signalingpathway is involved in a number of cellular functions, such as actingorganization, cell adhesion, cell migration, and cytokinesis (K. Rientoand A. J. Ridley, Nat Rev Mol Cell Biol, 2003, 4, 446-56). It is alsodirectly involved in regulating smooth muscle contraction (A. P. Somlyo,Nature, 1997, 389, 908-911). Upon activation of its receptor, RhoA isactivated and in turn it activates ROCK. Activated ROCK phosphorylatesthe myosin-binding subunit of myosin light chain phosphatase, whichinhibits activity of the phosphatase and leads to contraction.Contraction of the smooth muscle in the vasculature increases bloodpressure, leading to hypertension.

There is considerable evidence in the literature that the Rho/ROCKsignaling pathway plays an important role in signal transductioninitiated by several vasoactive factors, for example angiotensin II,urotension II, endothelin-1, serotonin, norepinephrine andplatelet-derived growth factor (PDGF). Many of these factors areimplicated in the pathogenesis of cardiovascular disease.

Additional studies in the literature, some using known ROCK inhibitorsfasudil (T. Asano et al., J. Pharmacol. Exp. Ther., 1987, 24, 1033-1040)or Y-27632 (M. Uehata et al., Nature, 1997, 389, 990-994) furtherillustrate the link between ROCK and cardiovascular disease. Forexample, ROCK expression and activity have been shown to be elevated inspontaneously hypertensive rats, suggesting a link to the development ofhypertension in these animals. The ROCK inhibitor Y-27632 (M. Uehata etal., Nature, ibid) was shown to significantly decrease blood pressure inthree rat models of hypertension, including the spontaneouslyhypertensive rat, renal hypertensive rat and deoxycortisone acetate salthypertensive rat models while having only a minor effect on bloodpressure in control rats, reinforcing the link between ROCK andhypertension.

Other studies suggest a link between ROCK and atherosclerosis. Forexample, gene transfer of a dominant negative form of ROCK suppressedneointimal formation following balloon injury in porcine femoralarteries. In a similar model, ROCK inhibitor Y-27632 also inhibitedneointimal formation in rats. In a porcine model of IL-1 beta-inducedcoronary stenosis, long term treatment by ROCK inhibitor fasudil wasshown to progressively reduce coronary stenosis as well as promote aregression of coronary constrictive remodeling.

Additional investigations suggest that a ROCK inhibitor would be usefulin treating other cardiovascular diseases. For example, in a rat strokemodel, fasudil was shown to reduce both the infarct size and neurologicdeficit. The ROCK inhibitor Y-27632 was shown to improve ventricularhypertrophy and function in a model of congestive heart failure in Dahlsalt-sensitive rats.

Other animal or clinical studies have implicated ROCK in additionaldiscuses including coronary vasospasm, cerebral vasospasm,ischemia/reperfusion injury, pulmonary hypertension, angina, renaldisease and erectile dysfunction.

The above studies provide evidence for a link between ROCK andcardiovascular diseases including hypertension, atherosclerosis,restenosis, stroke, heart failure, coronary vasospasm, cerebralvasospasm, ischemia/reperfusion injury, pulmonary hypertension andangina, as well as renal disease and erectile dysfunction. Given thedemonstrated effect of ROCK on smooth muscle, ROCK inhibitors may alsobe useful in other diseases involving smooth muscle hyper reactivity,including asthma and glaucoma. Furthermore, Rho-kinase has beenindicated as a drug target for the treatment of various other diseases,including airway inflammation and hyperresponsiveness, cancer, as wellas neurological disorders, such as spinal-cord injury, Alzheimerdisease, multiple sclerosis, stroke and neuropathic pain.

There remains an unmet medical need for new drugs to treatcardiovascular disease. A study published in 2003 estimated that almost29% of the adult U.S. population had hypertension in 1999-2000 (I.Hajjar et al., JAMA, 2003, 290, 199-206). Furthermore, 69% of thehypertensive individuals studied during this period did not have theirhypertension controlled at the time their blood pressure was measured.This figure was worse in hypertensive patients with diabetes, where 75%of those patients studied did not have their blood pressure controlledto the target level. Another more recent study showed similar results,with less than one-third of hypertensive patients studied having bloodpressure controlled to the target level (V. Andros, Am. J. Manag. Care,2005, 11, S215-S219). Therefore, despite the number of medicationsavailable to treat hypertension, including diuretics, beta blockers,angiotensin converting enzyme inhibitors, angiotensin blockers andcalcium channel blockers, hypertension remains poorly controlled orresistant to current medication for many patients. If not adequatelytreated, hypertension can lead to other cardiovascular diseases andorgan failure including coronary artery disease, stroke, myocardialinfarction, cardiac failure, renal failure and peripheral arterydisease.

Although there are many reports of ROCK inhibitors under investigation(see, for example, E. Hu and D. Lee, Expert Opin. Ther. Targets, 2005,9, 715-736), so far fasudil is the only marketed ROCK inhibitor. An i.v.formulation of fasudil was approved in Japan for treatment of cerebralvasospasm. There remains a need for new therapeutics, including ROCKinhibitors, for the treatment of cardiovascular diseases, cancer,neurological diseases, renal diseases, bronchial asthma, erectiledysfunction, and glaucoma.

BRIEF SUMMARY OF THE INVENTION

In a general aspect, the present invention is directed to the compoundsof the following formula (I):

wherein R₁, R₂, X and Y are as defined herein, as well as the tautomersthereof, and salts thereof. It has been found that the compounds offormula (I) have valuable pharmacological properties, particularly aninhibiting activity on Rho kinase.

In another aspect, the present invention is directed to a method ofinhibiting Rho kinase activity in an individual comprising administeringto the individual a compound described above.

In another aspect, the present invention is directed to a method oftreating a disease or disorder associated with the activation of Rhokinase comprising administering to an individual a compound describedabove.

In another aspect, the present invention is directed to a method oftreating a cardiovascular or disease or condition comprisingadministering to an individual a compound described above. Examples ofsuch diseases that may be treated include, for example, hypertension,atherosclerosis, stroke, heart failure, restenosis, myocardialinfarction, organ failure, renal failure, coronary artery disease,peripheral artery disease, coronary vasospasm, cerebral vasospasm,ischemia/reperfusion injury, pulmonary hypertension, angina, erectiledysfunction and renal disease.

In another aspect, the present invention is directed to a method oftreating diseases involving smooth muscle hyper reactivity includingasthma and glaucoma, comprising administering to an individual acompound described above.

In another aspect, the present invention is directed to a method oftreating diseases involving Rho-kinase under pathophysiologicalconditions, including airway inflammation and hyperresponsiveness,cancer, and various neurological diseases, comprising administering toan individual in need of such treatment a compound of the presentinvention as described above.

In yet additional aspects, the present invention is directed topharmaceutical compositions comprising the above-mentioned compounds,processes for preparing the above-mentioned compounds and intermediatesused in these processes.

DETAILED DESCRIPTION OF THE INVENTION

In an embodiment, there is provided compounds of the formula (I)

wherein:R₁ is chosen fromC₁₋₆alkyl, C₃₋₈cycloalkyl, C₃₋₈cycloalkylC₁₋₆alkyl, haloC₁₋₆alkyl,aminoC₁₋₆alkyl, hydroxyC₁₋₆alkyl, aryl, arylC.₁₋₆alkyl, heteroaryl,heteroarylC₁₋₆alkyl, heterocyclyl, —C₁₋₃alkylOaryl,—C(H)₀₋₁(C₁₋₆alkyl)₁₋₂aryl, —CH(OH)aryl, —C(OH)(CH₃)aryl,—CH[OC(O)C₁₋₆alkyl]aryl, —CH₂OCH₂aryl, —CH₂OC(O)C₁₋₆alkyl,—(CH₂)₁₋₃S(O)₀₋₂aryl, —(CH₂)₁₋₂S(O)₀₋₂C₁₋₆alkyl, —(CH₂)₁₋₃CO₂C₁₋₆alkyl,—(CH2)₁₋₃NHC₁₋₆alkyl, —(CH₂)₁₋₃NHC₁₋₆alkylC₃₋₈cycloalkyl, —(CH₂)₁₋₂CNand —CH(R₃)N(R₄)(R₅)wherein:R₃ is chosen fromH, aryl, C₁₋₆alkyl, —(CH₂)₁₋₃aryl and —(CH₂)₁₋₃heteroaryl;R₄ is chosen fromH, C₁₋₆alkyl, C₃₋₁₂cycloalkyl, C₃₋₇cycloalkylC₁₋₆alkyl, aryl,aryl(CH₂)₁₋₃, heteroaryl(CH₂)₁₋₃, C₁₋₃alkylO(CH₂)₁₋₃,tetrahydropyran-4-ylmethyl and C₁₋₃alkyl)₂N(CH₂)₂₋₄—; and R₅ is chosenfromH and C₁₋₆alkyl;or R₄ and R₅ together with the nitrogen atom they are connected to mayform a heterocyclyl group;wherein each aryl, arylalkyl, heteroaryl, heteroarylalkyl,cycloalkylalkyl, cycloalkyl and heterocyclyl group is optionallysubstituted with 1-3 groups selected fromhalogen, C₁₋₆alkoxy, C₃₋₈cycloalkyl, C₁₋₆alkyl, —CN, —NO₂, —OH, oxo,—CF₃, —OCF₃, —C₀₋₃, alkylCO₂H, C₁₋₆alkylCO₂-,C₁₋₆alkylsulfonylC₀₋₃alkyl-, —SO₂C₁₋₆alkylNR₆R₇, —C₀₋₃alkylSO₂NR₆R₇,—C₀₋₃C(O)NR₆R₇, aryl, heteroaryl, heteroarylC₁₋₃alkyl, heterocyclyl,heterocyclylSO₂-, arylC₁₋₃alkyl, aryloxy, arylthio and C₀₋₃NR₆R₇;wherein each aryl and heteroaryl group is optionally substituted with1-3 groups selected fromhalogen, C₁₋₆alkoxy, C₁₋₆alkyl, —CN, —NO₂, —OH, —CF₃, —OCF₃, —C(O)NR₈R₉,—SO₂NR₈R₉, —SO₂Me and amino optionally substituted by one or twoC₁₋₆alkyl groups or a C(O)C₁₋₆alkyl group;R₂ is chosen from H, halogen, C₁₋₆alkoxy, —CN, —CF₃ and C₁₋₆alkyl;R₆ and R₇ are independently selected from H, C₁₋₆alkyl, —C(O)C₁₋₆alkyland —C₁₋₆alkylNH₂; orR₆ and R₇, together with the nitrogen they are connected to may form apiperazine, piperidine or pyrrolidine ring;R₈ and R₉ are independently selected from H and methyl;R₁₀ is selected from H, Cl and F;X is chosen from C and N; andY is chosen from —NHC(O)—, —NHC(O)NH— and —NHC(O)O—;or a tautomer thereof or a salt thereof, preferably a pharmaceuticallyacceptable salt thereof. Preferably if R₁ is a C₁₋₆alkyl, and Y is—NHC(O)—, then R_(i) is not a methyl group.

In an embodiment, there is provided compounds of the formula (I)

wherein:R₁ is chosen fromC₃₋₈cycloalkyl, C₃₋₈cycloalkylC₁₋₆alkyl, haloC₁₋₆alkyl, aminoC₁₋₆alkyl,hydroxyC₁₋₆alkyl, aryl, arylC₁₋₆alkyl, heteroaryl, heteroarylC₁₋₆alkyl,heterocyclyl, —C₁₋₃alkylOaryl, —C(H)₀₋₁*(C₁₋₆alkyl)₁₋₂aryl, —CH(OH)aryl,—C(OH)(CH₃)aryl, —CH[OC(O)C₁₋₆alkyl]aryl, —CH₂OCH₂aryl,—CH₂OC(O)C₁₋₆alkyl, —(CH₂)₁₋₃S(O)₀₋₂aryl, —(CH₂)₁₋₂S(O)₀₋₂C₁₋₆alkyl,—(CH₂)₁₋₃CO₂C₁₋₆alkyl, —(CH₂)₁₋₃NHC₁₋₆alkyl,—(CH₂)₁₋₃NHC₁₋₆alkylC₃₋₈cycloalkyl, —(CH₂)₁₋₂CN and —CH(R₃)N(R₄)(R₅);wherein:R₃ is chosen fromH, aryl, C₁₋₆alkyl, —(CH₂)₁₋₃aryl and —(CH₂)₁₋₃heteroaryl;R₄ is chosen fromH, C₁₋₆alkyl, C₃₋₁₂cycloalkyl, C₃₋₇cycloalkylC₁₋₆alkyl, aryl,aryl(CH₂)₁₋₃, heteroaryl(CH₂)₁₋₃, C₁₋₃alkylO(CH₂)₁₋₃,tetrahydropyran-4-ylmethyl and (C₁₋₃alkyl)₂N(CH₂)₂₋₄—; and R₅ is chosenfromH and C₁₋₆alkyl;or R₄ and R₅ together with the nitrogen atom they are connected to mayform a heterocyclyl group;wherein each aryl, arylalkyl, heteroaryl, heteroarylalkyl,cycloalkylalkyl, cycloalkyl and heterocyclyl group is optionallysubstituted with 1-3 groups selected fromhalogen, C₁₋₆alkoxy, C₃₋₈cycloalkyl, C₁₋₆alkyl, —CN, —NO₂, —OH, oxo,—CF₃, —OCF₃, —C₁₋₃alkylCO₂H, C₁₋₆alkylCO₂-, C₁₋₆alkylsulfonyl₀₋₃alkyl-,—SO₂C—₁₋₆alkylNR₆R₇, —C₀₋₃alkylSO₂NR₆R₇, —C₀₋₃C(O)NR₆R₇, aryl,heteroaryl, heteroarylC₁₋₃alkyl, heterocyclyl, heterocyclylSO₂-,arylC₁₋₃alkyl, aryloxy, arylthio and C₀₋₃NR₆R₇;wherein each aryl and heteroaryl group is optionally substituted with1-3 groups selected fromhalogen, C₁₋₆alkoxy, C₁₋₆alkyl, —CN, —NO₂, —OH, —CF₃, —OCF₃, —C(O)NR₈R₉,—SO₂NR₈R.sub.₉—SO₂Me and amino optionally substituted by one or twoC₁₋₆alkyl groups or a C(O)C₁₋₆alkyl group;R₂ is chosen from H, halogen, C₁₋₆alkoxy, —CN, —CF₃ and C₁₋₆alkyl;R₆ and R₇ are independently selected from H, C₁₋₆alkyl, —C(O)C₁₋₆alkyland —C₁₋₆alkylNH₂; orR₆ and R₇, together with the nitrogen they are connected to may form apiperazine, piperidine or pyrrolidine ring;R₈ and R₉ are independently selected from H and methyl;R₁₀ is selected from H, Cl and F;X is chosen from C and N; andY is chosen from —NHC(O)—, —NHC(O)NH— and —NHC(O)O—;or a tautomer thereof or a salt thereof, preferably a pharmaceuticallyacceptable salt.

In another embodiment, there are provided compounds of the formula (I)as described above and wherein:

R₁ is chosen from

C₃₋₈cycloalkyl, C₃₋₈cycloalkylC₁₋₆alkyl, phenyl, benzyl, phenylethyl,thienyl, pyridyl, isoxazolyl, pyrazolyl, thienylmethyl, piperidinyl,piperazinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl,—CH₂Ophenyl, —CH(C₁₋₃alkyl)phenyl, —CH(OH)phenyl, —C(OH)(CH₃)phenyl,—CH[OC(O)CH₃]phenyl, —CH₂OCH₂phenyl, —CH₂OC(O)C₁₋₆alkyl,—(CH₂)₁₋₃S(O)₀₋₂phenyl, —(CH₂)₁₋₂S(O)₀₋₂C₁₋₆alkyl,—(CH₂)₁₋₃CO₂C₁₋₆alkyl, —(CH₂)₁₋₃NHC₁₋₆alkyl,—(CH₂)₁₋₃NHC₁₋₆alkylC₃₋₈cycloalkyl, —(CH₂)₁₋₃CN and —CH(R₃)N(R₄)(R₅);wherein:R₃ is chosen fromH, phenyl, C₁₋₆alkyl, benzyl phenylethyl and pyridylmethyl;R₄ is chosen fromH, C₁₋₆alkyl, C₃₋₁₂cycloalkyl, C₃₋₇cycloalkylC₁₋₆alkyl, phenyl, benzyl,thienylethyl, C₁₋₃ alkylO(CH₂)₁₋₃, tetrahydropyran-4-ylmethyl and(C₁₋₃)₂N(CH₂)₂₋₄—; and R₅ chosen fromH and C₁₋₆alkyl;or R₄ and R₅ together with the nitrogen atom they are connected to mayform a piperidine, piperazine or thiomorpholine group;wherein each cycloalkyl, cycloalkylalkyl, phenyl, benzyl, phenylethey,thienyl, pyridyl, isoxazolyl, pyrazolyl, thienylmethyl, piperidine,piperazinyl, pyrrolidinyl, tetrahydrofuranyl, tetrahydropyranyl, andthiomorpholinyl group is optionally substituted with 1-3 groups selectedfromhalogen, C₁₋₆alkoxy, C₁₋₆alkyl, —CN, —NO₂, —OH, —CF₃, —OCF₃,C₁₋₆alkylCO₂-, C₁₋₆alkylsulfonyl, phenyl, pyrimidyl, pyridyl,morpholinyl, benzyl, phenyloxy and phenylthio and amino optionallysubstituted by one or two C₁₋₆alkyl groups or a C(O)C₁₋₆alkyl group;wherein each phenyl, benzyl, pyrimidinyl and pyridyl group is optionallysubstituted with 1-3 groups selected fromhalogen, C₁₋₆alkoxy, C₁₋₆alkyl, —CN, —NO₂, —OH, —CF₃, —OCF₃, —C(O)NR₈R₉,—SO₂NR₈R₉, —SO₂Me and amino optionally substituted by one or twoC₁₋₆alkyl groups or a C(O)C₁₋₆alkyl group;R₂ is chosen from H, Br, Cl, —CN, —CF₃ and methyl;R₈ and R₉ are independently selected from H and methyl;R₁₀ is selected from H, Cl and F;X is chosen from C and N; andY is chosen from —NHC(O)—, —NHC(O)NH— and —NHC(O)O—;or a tautomer thereof or a salt thereof, preferably a pharmaceuticallyacceptable salt thereof.

In a further embodiment, there are provided compounds of the formula (I)as described above and wherein:

R₁ is chosen from

cyclopentyl, cyclohexyl, phenyl, benzyl, phenylethyl, thienylmethyl,piperidinyl, pyrrolodinyl, —CH₂Sphenyl and —CH(R₃)N(R₄)(R₅)

wherein:

R₃ is chosen from

H, phenyl, C₁₋₆alkyl, benzyl and phenylethyl;

R₄ is chosen from

H, C₁₋₆alkyl, C₃₋₁₂cycloalkyl, C₃₋₇cycloalkylmethyl, benzyl,thienylethyl, and tetrahydropyran-4-ylmethyl;

and R₅ is chosen from

H and methyl;

or R₄ and R₅ together with the nitrogen atom they are connected to mayform a piperidine group;

wherein each cyclopentyl, cyclohexyl, phenyl, benzyl, phenylethyl,thienylmethyl, piperidinyl and pyrrolidinyl group is optionallysubstituted with 1-3 groups selected from

halogen, C₁₋₆alkoxy, C₁₋₆alkyl, —CN, —NO₂, —OH—CF₃, —OCF₃, phenyl andamino optionally substituted by one or two C₁₋₆alkyl groups or aC(O)C₁₋₆alkyl group;

wherein each phenyl group is optionally substituted with 1-3 groupsselected from

halogen, C₁₋₆alkoxy, C₁₋₆alkyl, —CN, —NO₂, —OH, —CF₃, —OCF₃, and aminooptionally substituted by one or two C₁₋₆alkyl groups or a C(O)C₁₋₆alkylgroup;

R₂ is chosen from H, Br and Cl;

R₁₀ is H;

X is chosen from C and N; and

Y is —NHC(O)—

or a tautomer thereof or a salt thereof, preferably a pharmaceuticallyacceptable salt thereof.

In still a further embodiment of the invention, there are providedcompounds of the formula (I) selected from the group below or a tautomerthereof or a salt thereof, preferably a pharmaceutically acceptable saltthereof:

Structure Name

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(4-methyl-piperazin-1-yl)-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(cyclohexylmethyl-amino)-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(4-hydroxy-piperidin-1-yl)-2-phenyl-acetamide

2-Benzylamino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenyl-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-thiomorpholin-4-yl-propionamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(1,2,3,4-tetrahydro-naphthalen-1-ylamino)- acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(2-thiophen-2-yl-ethylamino)-propionamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methylamino-2-phenyl-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclopropylamino-2-phenyl-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(ethyl-methyl-amino)-2-phenyl-acetamide

(S)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-phenyl-propionamide

(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-phenyl-propionamide

(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenyl-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclobutylamino-2-phenyl-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(cyclopropylmethyl-amino)-2-phenyl-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(3-ethoxy-propylamino)-2-phenyl-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-[(2-dimethylamino-ethyl)-ethyl-amino]-2-phenyl- acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-[(tetrahydro-pyran-4-ylmethyl)-amino]-acetamide

2-(Adamantan-1-ylamino)-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-[(pyridin-2-ylmethyl)-amino]-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-[(pyridin-3-ylmethyl)-amino]-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-[(pyridin-4-ylmethyl)-amino]-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(cyclohexylmethyl-amino)-propionamide

(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)- carbamic acid isopropylester

2-Dimethylamino-N-(1-oxo-1,2-dihydro-isoquinolin- 6-yl)-acetamide

2-(Cyclohexylmethyl-amino)-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide

2-Dimethylamino-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenyl-acetamide

Acetic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-ylcarbamoyl)-phenyl-methyl ester

1-Benzyl-3-(1-oxo-1,2-dihydro-isoquinolin-6-yl)- urea

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-hydroxy-2-phenyl-acetamide

(R)-2-Amino-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)- 2-phenyl-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(4-chloro-phenyl)-3-methyl-butyramide

2,5-Dichloro-thiophene-3-carboxylic acid (1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

N-(1-Oxo-1,2-dihydro-isoquinolin-6-yl)-2- phenylsulfanyl-nicotinamide

2-(3-Methoxy-phenyl)-N-(1-oxo-1,2-dihydro- isoquinolin-6-yl)-acetamide

2-(4-Chloro-phenoxy)-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-nicotinamide

2-(4-Chloro-phenoxy)-2-methyl-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-propionamide

N-(1-Oxo-1,2-dihydro-isoquinolin-6-yl)-succinamic acid ethyl ester

Thiophene-2-carboxylic acid (1-oxo-1,2-dihydro- isoquinolin-6-yl)-amide

1-(4-Chloro-phenyl)-cyclopentanecarboxylic acid(1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

2-(4-Chloro-phenoxy)-N-(1-oxo-1,2-dihydro- isoquinolin-6-yl)-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2- methyl-benzamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2- phenyl-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2,3,6-trifluoro-benzamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-5-fluoro-2-methyl-benzamide

2-Chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-nitro-benzamide

2-Bromo-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin- 6-yl)-benzamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(4-fluoro-phenyl)-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2,2-dimethyl-propionamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3,3- dimethyl-butyramide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenylsulfanyl-nicotinamide

2,4-Dichloro-N-(7-chloro-1-oxo-1,2-dihydro- isoquinolin-6-yl)-benzamide

5-Methyl-3-phenyl-isoxazole-4-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2,4,6-trifluoro-benzamide

2,3-Dichloro-N-(7-chloro-1-oxo-1,2-dihydro- isoquinolin-6-yl)-benzamide

1-(4-Chloro-phenyl)-cyclopentanecarboxylic acid(4-oxo-3,4-dihydro-quinazolin-7-yl)-amide

Piperidine-4-carboxylic acid (4-oxo-3,4-dihydro- quinazolin-7-yl)-amide

2-Benzylamino-N-(4-oxo-3,4-dihydro-quinazolin-7- yl)-acetamide

1-Benzyl-piperidine-4-carboxylic acid (4-oxo-3,4-dihydro-quinazolin-7-yl)-amide

Piperidine-3-carboxylic acid (4-oxo-3,4-dihydro- quinazolin-7-yl)-amide

Pyrrolidine-2-carboxylic acid (4-oxo-3,4-dihydro- quinazolin-7-yl)-amide

2-Amino-4-methyl-pentanoic acid (4-oxo-3,4-dihydro-quinazolin-7-yl)-amide

(R)-2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)- 3-phenyl-propionamide

(S)-2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)- 3-phenyl-propionamide

2-(Cyclohexylmethyl-amino)-N-(4-oxo-3,4-dihydro-isoquinolin-7-yl)-acetamide

2-Methylamino-N-(4-oxo-3,4-dihydro-quinazolin-7- yl)-2-phenyl-acetamide

2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2- phenyl-acetamide

2-Cyclopropylamino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-phenyl-acetamide

(R)-2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)- 2-phenyl-acetamide

(R)-Pyrrolidine-2-carboxylic acid (4-oxo-3,4-dihydro-quinazolin-7-yl)-amide

(R)-2-Amino-3-methyl-N-(4-oxo-3,4-dihydro- quinazolin-7-yl)-butyramide

2-(Cyclopropylmethyl-amino)-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-acetamide

N-(4-Oxo-3,4-dihydro-quinazolin-7-yl)-2-(2-thiophen-2-yl-ethylamino)-acetamide

2-(Cyclohexyl-methyl-amino)-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-acetamide

N-(6-Chloro-4-oxo-3,4-dihydro-quinazolin-7-yl)-2-dimethylamino-2-phenyl-acetamide

N-(6-Chloro-4-oxo-3,4-dihydro-quinazolin-7-yl)-2-cyclopropylamino-2-phenyl-acetamide

2,5-Dimethyl-2H-pyrazole-3-carboxylic acid (4-oxo-3,4-dihydro-quinazolin-7-yl)-amide

2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-(4-fluoro-phenyl)-propionamide

2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(3-chloro-phenyl)-acetamide

(R)-2-Amino-2-cyclohexyl-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide

(R)-2-Amino-2-(4-chloro-phenyl)-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide

R)-Pyrrolidine-2-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(S)-Pyrrolidine-2-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin- 6-yl)-acetamide

Piperidine-4-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-(4-chloro-phenyl)-propionamide

(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-p-tolyl-acetamide

(S)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-cyclohexyl-propionamide

(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-cyclohexyl-propionannide

(R)-2-Amino-4,4-dimethyl-pentanoic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(S)-2-Amino-4,4-dimethyl-pentanoic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

2-Chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-methanesulfonyl-benzamide

2-Chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-morpholin-4-yl-benzamide

(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-naphthalen-2-yl-propionamide

(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-naphthalen-1-yl-propionamide

(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-pyridin-4-yl-propionamide

2-Methyl-2-methylamino-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-propionamide

2-Amino-2-methyl-N-(1-oxo-1,2-dihydro-isoquinolin- 6-yl)-propionamide

(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methoxy-2-phenoxy-acetamide

(S)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methoxy-2-phenyl-acetamide

3-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin- 6-yl)-propionamide

(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-methyl-butyramide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3,3,3-trifluoro-2-methoxy-2-phenyl-propionamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-oxo-2-phenyl-acetamide

(R)-Piperidine-2-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

2-tert-Butylamino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide

(R)-2-Methoxy-N-(7-methoxy-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenyl-acetamide

(S)-2-Methoxy-N-(7-methoxy-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenyl-acetamide

(R)-2-Amino-2-cyclohexyl-N-(7-methoxy-1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide

(S)-2-Amino-2-cyclohexyl-N-(7-methoxy-1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide

4-Bromo-2-chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-benzamide

2-Chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-6-methanesulfonyl-benzamide

(R)-Tetrahydro-furan-2-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(S)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-hydroxy-2-phenyl-acetamide

(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-hydroxy-2-phenyl-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2- cyano-benzamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methyl-4-nitro-benzamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-nitro-2-trifluoromethyl-benzamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-morpholin-4-ylmethyl-benzamide

1-Amino-cyclohexanecarboxylic acid (1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclohexyl-acetamide

(R)-2-Amino-4-methyl-pentanoic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(S)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclohexyl-acetamide

(S)-2-Amino-4-methyl-pentanoic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(S)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-methyl-butyramide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(4-methyl-piperazin-1-ylmethyl)-benzamide

1,2,3,4-Tetrahydro-isoquinoline-5-carboxylic acid(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

1,2,3,4-Tetrahydro-isoquinoline-8-carboxylic acid(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

1-Methyl-piperidine-4-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)- 3-methyl-succinamicacid methyl ester

2-Chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-nitro-benzamide

2-Chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-5-nitro-benzamide

(S)-Tetrahydro-furan-2-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-methylsulfanyl-propionamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2- cyano-acetamide

2-Bromo-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-methyl-benzamide

Tetrahydro-pyran-4-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3- phenyl-succinamicacid

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)- malonamic acid ethylester

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methylsulfanyl-acetamide

(S)-Pyrrolidine-3-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(S)-Piperidine-3-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(R)-Piperidine-3-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methanesulfonyl-acetamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2- phenyl-malonamic acid

(S)-Piperidine-2-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

1-Methanesulfonyl-4-methyl-piperidine-4-carboxylic acid(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)- amide

2-Chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-nitro-benzamide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-methanesulfonyl-benzamide

(R)-Pyrrolidine-3-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

4-Amino-cyclohexanecarboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

4-Amino-cyclohexanecarboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

4-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-ylcarbamoyl)-cyclohexanecarboxylic acid

4-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-ylcarbamoyl)-cyclohexanecarboxylic acid

(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-isopropoxy-2-phenyl-acetamide

(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenoxy-propionamide

(S)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenoxy-propionamide

4-Phenyl-piperidine-4-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

4-(4-Chloro-phenyl)-piperidine-4-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

4-Benzyl-piperidine-4-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(R)-Piperidine-3-carboxylic acid (1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(S)-Piperidine-3-carboxylic acid (1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

1-Methyl-piperidine-4-carboxylic acid (1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-hydroxy-3-methyl-butyramide

Piperazine-2-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

4-Methyl-piperidine-4-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(3S,4S)-3-Methyl-piperidine-4-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(trans)-4-Phenyl-piperidine-3-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

Acetic acid 4-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-ylcarbamoyl)-cyclohexyl ester

(1R,3S)-3-Amino-cyclopentanecarboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

4-Hydroxy-cyclohexanecarboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(S)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclohexyl-2-hydroxy-acetamide

(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclohexyl-2-hydroxy-acetamide

(S)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-hydroxy-2-phenyl-propionamide

(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-hydroxy-2-phenyl-propionamide

(1R,3S)-Amino-cyclohexanecarboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(1R,3S)-3-Amino-cyclohexanecarboxylic acid (7-methoxy-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(3R,4S)-3-Methyl-piperidine-4-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

4-Dimethylamino-cyclohexanecarboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

3-Amino-cyclobutanecarboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

3-Amino-cyclobutanecarboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

4-Amino-1-(4-chloro-phenyl)-cyclohexanecarboxylic acid(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)- amide

4-Amino-1-(4-chloro-phenyl)-cyclohexanecarboxylic acid(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)- amide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-methanesulfonyl-2-methyl-benzamide

(1S,3S)-3-Amino-cyclohexanecarboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(S)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclohexyl-2-isopropylamino-acetamide

4-(4-Fluoro-phenyl)-pyrrolidine-3-carboxylic acid (1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(1S,2S)-2-Methyl-4-oxo-cyclohexanecarboxylic acid(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

3-Phenyl-pyrrolidine-3-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

1-Isopropyl-piperidine-4-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

4-Phenyl-pyrrolidine-3-carboxylic acid (1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

1-Cyclohexyl-piperidine-4-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

1-Pyridin-4-ylmethyl-piperidine-4-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methyl-4-(piperazine-1-sulfonyl)-benzamide

(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(2-chloro-phenyl)-2-hydroxy-acetamide

(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(3-chloro-phenyl)-2-hydroxy-acetamide

(2S,3R)-2-Amino-3-methyl-pentanoic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2- phenyl-isobutyramide

1-Benzyl-piperidine-4-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(trans)-4-Phenyl-pyrrolidine-3-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(trans)-4-(4-Fluoro-phenyl)-pyrrolidine-3-carboxylic acid(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)- amide

(3R,4S)-1,3-Dimethyl-piperidine-4-carboxylic acid(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

5-Phenyl-piperidine-3-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

1,2,3,4-Tetrahydro-isoquinolin-7-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

1,2,3,4-Tetrahydro-isoquinolin-6-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

4-(3-Amino-propane-1-sulfonyl)-2-chloro-N-(7-dihydro-isoquinolin-6-yl)-benzamide

(trans)-4-(3-Bromo-phenyl)-pyrrolidine-3-carboxylic acid(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)- amide

(trans)-4-(4-Chloro-phenyl)pyrrolidine-3-carboxylic acid(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)- amide

(1R,5S,6R)-3-Aza-bicyclo[3.1.10]hexane-6- carboxylic acid(7-chloro-1-oxo-1,2-dihydro- isoquinolin-6-yl)-amide

(1R,5S,6S)-3-Aza-bicyclo[3.1.0]hexane-6- carboxylic acid(7-chloro-1-oxo-1,2-dihydro- isoquinolin-6-yl)-amide

(trans)-4-(3-Bromo-phenyl)-pyrrolidine-3-carboxylic acid(6-chloro-4-oxo-3,4-dihydro-quinazolin-7-yl)- amide

(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(4-chloro-phenyl)-2-hydroxy-propionamide

(R)-N-(6-Chloro-4-oxo-3,4-dihydro-quinazolin-7-yl)-2-(4-chloro-phenyl)-2-hydroxy-propionamide

(R)-2-(4-Chloro-phenyl)-2-hydroxy-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-propionamide

1-Methyl-piperidine-4-carboxylic acid (7-bromo-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

1-Methyl-piperidine-4-carboxylic acid (7-fluoro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

1-Methyl-piperidine-4-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

1-Methyl-piperidine-4-carboxylic acid (7-cyano-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(trans)-4-Phenyl-pyrrolidine-3-carboxylic acid (7-bromo-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(trans)-4-(4-Chloro-phenyl)-pyrrolidine-3-carboxylic acid(7-bromo-1-oxo-1,2-dihydro-isoquinolin-6-yl)- amide

(trans)-4-Phenyl-pyrrolidine-3-carboxylic acid (5-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

(trans)-4-Phenyl-pyrrolidine-3-carboxylic acid (7-chloro-5-fluoro-1-oxo-1,2-dihydro-isoquinolin-6-yl)- amide

In an additional embodiment of the invention, there are providedcompounds of the formula (I) selected from the group below or a tautomerthereof or a salt thereof, preferably a pharmaceutically acceptable saltthereof:

-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2(4-methyl-piperazin-1yl)-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(cyclohexylmethyl-amino-)-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2(4-hydroxy-piperidin-1    yl)-2-phenyl-acetamide;-   2-Benzylamino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenyl-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-thiomorpholin-4-yl-propionamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(1,2,3,4-tetrahydro-naphthalen-1-ylamino)-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(2-thiophen-2-yl-ethylamino)-propionamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methylamino-2-phenyl-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-cyclopropylamino-2-phenyl-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-ethyl-methyl-amino)-2-phenyl-acetamide;-   (S)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-phenyl-propionamide;-   (R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-phenyl-propionamide;-   (R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenyl-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclobutylamino-2-phenyl-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclopropylmethyl-amino)-2-phenyl-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(3-ethoxy-propylamino)-2-phenyl-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-[(2-dimethylamino-ethyl)-ethyl-amino]-2-phenyl-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-[(tetrahydro-pyran-4-yl-methyl)-amino]-acetamide;-   2-(Adamantan-1-ylamino)-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-[(pyridin-2-ylmethyl)-amino]-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-[(pyridin-3-ylmethyl)-amino]-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-[(pyridin-4-ylmethyl)-amino]-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(cyclohexylmethyl-amino)-propionamide;-   (7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-carbamic acid    isopropyl ester;-   2-Dimethylamino-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide;-   2-(Cyclohexylmethyl-amino)-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide;-   2-Dimethylamino-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-phenyl-acetamide;-   Acetic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-ylcarbamoyl)-phenyl-methyl    ester;-   1-Benzyl-3-(1-oxo-1,2-dihydro-isoquinolin-6yl)-urea;-   N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-hydroxy-2-phenyl-acetamide;-   (R)-2-Amino-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenyl-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(4-chloro-phenyl)-3-methyl-butyramide;-   2,5-Dichloro-thiophene-3-carboxylic acid    (1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   N-(1-Oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenylsulfanyl-nicotinamide;-   2-(3-Methoxy-phenyl)-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide;-   2-(4-Chloro-phenoxy)-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-nicotinamide;-   2-(4-Chloro-phenoxy)-2-methyl-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-propionamide;-   N-(1-Oxo-1,2-dihydro-isoquinolin-6-yl)-succinamic acid ethyl ester;-   Thiophene-2-carboxylic acid    (1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   1-(4-Chloro-phenyl)-cyclopentanecarboxylic acid    (1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   2-(4-Chloro-phenoxy)-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methyl-benzamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenyl-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2,3,6-trifluoro-benzamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-5-fluoro-2-methyl-benzamide;-   2-Chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-nitro-benzamide;-   2-Bromo-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-benzamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(4-fluoro-phenyl)-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2,2-dimethyl-propionamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3,3-dimethyl-butyramide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenylsulfanyl-nicotinamide;-   2,4-Dichloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-benzamide;-   5-Methyl-3-phenyl-isoxazole-4-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-yl)-2,4,6-trifluoro-benzamide;-   2,3-Dichloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-benzamide;-   2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-(4-fluoro-phenyl)-propionamide;-   2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(3-chloro-phenyl)-acetamide;-   (R)-2-Amino-2-cyclohexyl-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide;-   (R)-2-Amino-2-(4-chloro-phenyl)-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide;-   (R)-Pyrrolidine-2-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (S)-Pyrrolidine-2-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide;-   Piperidine-4-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-(4-chloro-phenyl)-propionamide;-   (R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-p-tolyl-acetamide;-   (S)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-cyclohexyl-propionamide;-   (R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-cyclohexyl-propionamide;-   (R)-2-Amino-4,4-dimethyl-pentanoic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (S)-2-Amino-4,4-dimethyl-pentanoic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   2-Chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-methanesulfonyl-benzamide;-   2-Chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-morpholin-4-yl-benzamide;-   (R)-2-Amino-N-(7chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-naphthalen-2-yl-propionamide;-   (R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-naphthalen-1-yl-propionamide;-   (R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-pyridin-4yl-propionamide;-   2-Methyl-2-methylamino-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-propionamide;-   2-Amino-2-methyl-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-propionamide;-   (R)—N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methoxy-2-phenyl-acetamide;-   (S)—N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methoxy-2-phenyl-acetamide;-   3-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-propionamide;-   (R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-meth-yl-butyramide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3,3,3-trifluoro-2-methoxy-2-phenyl-propionamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-oxo-2-phenyl-acetamide;-   (R)-Piperidine-2-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   2-tert-Butylamino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide;-   (R)-2-Methoxy-N-(7-methoxy-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenyl-acetamide;-   (S)-2-Methoxy-N-(7-methoxy-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenyl-acetamide;-   (R)-2-Amino-2-cyclohexyl-N-(7-methoxy-1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide;-   (S)-2-Amino-2-cyclohexyl-N-(7-methoxy-1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide;-   4-Bromo-2-chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-benzamide;-   2-Chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-5-methanesulfonyl-benzamide;-   (R)-Tetrahydro-furan-2-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (S)—N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-hydroxy-2-phenyl-acetamide;-   (R)—N-(7Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-hydroxy-2-phenyl-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyano-benzamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methyl-4-nitro-benzamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-nitro-2-trifluoromethyl-benzamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-morpholin-4-ylmethyl-benzamide;-   1-Amino-cyclohexanecarboxylic acid    (1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclohexyl-acetamide;-   (R)-2-Amino-4-methyl-pentanoic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (S)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclohexyl-acetamide;-   (S)-2-Amino-4-methyl-pentanoic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (S)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-methyl-butyramide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(4-methyl-piperazin-1-ylmethyl)-benzamide;-   1,2,3,4-Tetrahydro-isoquinoline-5-carboxylic acid    (7-chloro-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   1,2,3,4-Tetrahydro-isoquinoline-8-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   1-Methyl-piperidine-4-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (R)—N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-methyl-succinamic    acid methyl ester;-   2-Chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-nitro-benzamide;-   2-Chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-5-nitro-benzamide;-   (S)-Tetrahydro-furan-2-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-methylsulfanyl-propionamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyano-acetamide;-   2-Bromo-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-methyl-benzamide;-   Tetrahydro-pyran-4-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-phenyl-succinamic    acid;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-malonamic acid ethyl    ester;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methylsulfanyl-acetamide;-   (S)-Pyrrolidine-3-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (S)-Piperidine-3-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (R)-Piperidine-3-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methanesulfonyl-acetamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenyl-malonamic    acid;-   (S)-Piperidine-2-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   1-Methanesulfonyl-4-methyl-piperidine-4-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   2-Chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-nitro-benzamide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-nitro-benzamide;-   (R)-Pyrrolidine-3-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   4-Amino-cyclohexanecarboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   4-Amino-cyclohexanecarboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   4-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-ylcarbamoyl)-cyclohexanecarboxylic    acid;-   (R)—N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-isopropoxy-2-phenyl-1-acetamide;-   (R)—N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenoxy-propionamide;-   (S)—N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenoxy-propionamide;-   4-Phenyl-piperidine-4-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   4-(4-Chloro-phenyl)-piperidine-4-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   4-Benzyl-piperidine-4-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (R)-Piperidine-3-carboxylic acid    (1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (S)-Piperidine-3-carboxylic acid    (1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   1-Methyl-piperidine-4-carboxylic acid    (1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (R)—N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-hydroxy-3-methyl-butyramide;-   Piperazine-2-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   4-Methyl-piperidine-4-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (3S,4S-Methyl-piperidine-4-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (3R,4S)-4-Phenyl-piperidine-3-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   Acetic acid    4-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-ylcarbamoyl)-cyclohexyl    ester (1R,3S)-3-Amino-cyclopentanecarboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   4-Hydroxy-cyclohexanecarboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (S)—N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclohexyl-2-hydroxy-acetamide;-   (R)—N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclohexyl-2-hydroxy-acetamide;-   (S)—N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-hydroxy-2-phenyl-propionamide;-   (R)—N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-hydroxy-2-phenyl-propionamide;-   (1R,3S)-3-Amino-cyclohexanecarboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (1R,3S)-3-Amino-cyclohexanecarboxylic acid    (7-methoxy-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (3R,4S)-3-Methyl-piperidine-4-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   4-Dimethylamino-cyclohexanecarboxylic acid    (7-chloro-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   3-Amino-cyclobutanecarboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   4-Amino-1-(4-chloro-phenyl)-cyclohexanecarboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6yl)-4-methanesulfonyl-2-methyl-benzamide;-   (1S,3S)-3-Amino-cyclohexanecarboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (S)—N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclohexyl-2-isopropylamino-acetamide;-   4-(4-Fluoro-phenyl)-pyrrolidine-3-carboxylic acid    (1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (1 S,2S)-2-Methyl-4-oxo-cyclohexanecarboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   3-Phenyl-pyrrolidine-3-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   1-Isopropyl-piperidine-4-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   4-Phenyl-pyrrolidine-3-carboxylic acid    (1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   1-Cyclohexyl-piperidine-4-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   1-Pyridin-4-ylmethyl-piperidine-4-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methyl-4(piperazine-1-sulfonyl)-benzamide;-   (R)—N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(2-chloro-phenyl)-2-hydroxy-acetamide;-   (R)—N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(3-chloro-phenyl)-2-hydroxy-acetamide;-   (2S,3R)-2-Amino-3-methyl-pentanoic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenyl-isobutyramide;-   1-Benzyl-piperidine-4-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (3R,4S)-4-Phenyl-pyrrolidine-3-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (3R,4S)-4-(4-Fluoro-phenyl)-pyrrolidine-3-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (3R,4S)-1,3-Dimethyl-piperidine-4-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   5-Phenyl-piperidine-3-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   1,2,3,4-Tetrahydro-isoquinolin-7-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   1,2,3,4-Tetrahydro-isoquinolin-6-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   4-(3-Amino-propane-1-sulfonyl)-2-chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-benzamide;-   4-(3-Bromo-phenyl)-pyrrolidine-3-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   4-(4-chloro-phenyl)-pyrrolidine-3-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (1R,5S,6R)-3-Aza-bicyclo[3.1.0]hexane-6-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (1R,5S,6S)-3-Aza-bicyclo[3.1.0]hexane-6-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   (R)—N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(4-chloro-phenyl)-2-hydroxy-propionamide;-   1-Methyl-piperidine-4-carboxylic acid    (7-bromo-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   1-Methyl-piperidine-4-carboxylic acid    (7-fluoro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   1-Methyl-piperidine-4-carboxylic acid    (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   1-Methyl-piperidine-4-carboxylic acid    (7-cyano-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide;-   4-Phenyl-pyrrolidine-3-carboxylic acid    (7-bromo-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide; and-   4-(4-Chloro-phenyl)-pyrrolidine-3-carboxylic acid    (7-bromo-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide.

In another embodiment of the invention, there are provided compounds ofthe formula (I) selected from the group below or a tautomer thereof or asalt thereof, preferably a pharmaceutically acceptable salt thereof:

-   1-(4-Chloro-phenyl)-cyclopentanecarboxylic acid    (4-oxo-3,4-dihydro-quinazolin-7-yl)-amide;-   Piperidine-4-carboxylic acid    (4-oxo-3,4-dihydro-quinazolin-7-yl)-amide;-   2-Benzylamino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-acetamide;-   1-Benzyl-piperidine-4-carboxylic acid    (4-oxo-3,4-dihydro-quinazolin-7-yl)-amide;-   Piperidine-3-carboxylic acid    (4-oxo-3,4-dihydro-quinazolin-7-yl)-amide;-   Pyrrolidine-2-carboxylic acid    (4-oxo-3,4-dihydro-quinazolin-7-yl)-amide;-   2-Amino-4-methyl-pentanoic acid    (4-oxo-3,4-dihydro-quinazolin-7-yl)-amide;-   (R)-2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-3-phenyl-propionamide;-   (S)-2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-3-phenyl-propionamide;-   2-(Cyclohexylmethyl-amino)-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-acetamide;-   2-Methylamino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-phenyl-acetamide;-   2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-phenyl-acetamide;-   2-Cyclopropylamino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-phenyl-acetamide;-   (R)-2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-phenyl-acetamide;-   (R)-Pyrrolidine-2-carboxylic acid    (4-oxo-3,4-dihydro-quinazolin-7-yl)-amide;-   (R)-2-Amino-3-methyl-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-butyramide;-   2-(Cyclopropylmethyl-amino)-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-acetamide;-   N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-(2-thiophen-2-yl-ethylamino)-acetamide;-   2-(Cyclohexyl-methyl-amino)-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-acetamide;-   N-(6-Chloro-4-oxo-3,4-dihydro-quinazolin-7-yl)-2-dimethylamino-2-phenyl-acetamide;-   N-(6-Chloro-4-oxo-3,4-dihydro-quinazolin-7-yl)-2-cyclopropylamino-2-phenyl-acetamide;-   2,5-Dimethyl-2H-pyrazole-3-carboxylic acid    (4-oxo-3,4-dihydro-quinazolin-7-yl)-amide;-   4-(3-Bromo-phenyl)-pyrrolidine-3-carboxylic acid    (6-chloro-4-oxo-3,4-dihydro-quinazolin-7-yl)-amide;-   (R)—N-(6-Chloro-4-oxo-3,4-dihydro-quinazolin-7yl)-2-(4-chloro-phenyl)-2-hydroxy-propionamide;-   and-   (R)-2-(4-Chloro-phenyl)-2-hydroxy-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-propionamide;

For the compounds disclosed hereinabove in this application, in theevent the nomenclature is in conflict with the structure, it shall beunderstood that the compound is defined by the structure.

In another embodiment of the invention the above described compounds offormula (I) are used in methods of treating a disease-state or conditionmediated by Rho kinase in an individual, the method comprisingadministering to the individual an effective amount of a compound offormula (I) or tautomer thereof, or salt thereof, preferably apharmaceutically acceptable salt thereof.

In another embodiment of the invention the above described compounds offormula (I) are used in methods of treating a cardiovascular disease orcondition in an individual, the method comprising administering to theindividual an effective amount of a compound of formula (I) or tautomerthereof, or salt thereof, preferably a pharmaceutically acceptable saltthereof.

Preferred cardiovascular disease or conditions are hypertension,atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm,cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension,angina, myocardial infarction, peripheral artery disease, coronaryartery disease and combinations thereof.

In yet another embodiment of the invention the above described compoundsof formula (I) are used in methods of treating renal disease, erectiledysfunction, asthma, glaucoma, or organ failure resulting fromhypertension in an individual, the method comprising administering tothe individual an effective amount of a compound of formula (I) ortautomer thereof, or salt thereof, preferably a pharmaceuticallyacceptable salt thereof.

Any compounds of this invention containing one or more asymmetric carbonatoms may occur as racemates and racemic mixtures, single enantiomers,diastereomeric mixtures and individual diastereomers. All such isomericforms of these compounds are expressly included in the presentinvention. Each stereogenic carbon may be in the R or S configuration,or a combination of configurations.

Some of the compounds of formula (I) can exist in more than onetautomeric form. The invention includes methods using all suchtautomers.

The compounds of the invention are meant to embrace compounds of Formula(I) as herein described, including the prodrugs, and the solvates andhydrates thereof.

All terms as used herein in this specification, unless otherwise stated,shall be understood in their ordinary meaning as known in the art. Forexample, “C₁₋₄alkyl” is a saturated aliphatic hydrocarbon monovalentradical containing 1-4 carbons such as methyl, ethyl, n-propyl,1-methylethyl (isopropyl), n-butyl or t-butyl; “C₁₋₄ alkoxy” is a C₁₋₄alkyl with a terminal oxygen, such as methoxy, ethoxy, propoxy, butoxy.All alkyl, alkenyl and alkynyl groups shall be understood as beingbranched or unbranched, cyclized or uncyclized where structurallypossible and unless otherwise specified. Other more specific definitionsare as follows: Carbocycles including Cycloalkyl and Cycloalkenylgroups, are hydrocarbon rings containing from three to twelve carbonatoms. These carbocycles may be either aromatic or non-aromatic ringsystems, monocyclic or polycyclic. The non-aromatic ring systems may bemono- or polyunsaturated. Preferred carbocycles include but are notlimited to cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl,cyclohexyl, cyclohexenyl, cycloheptanyl, cycloheptenyl, phenyl, indanyl,indenyl, benzocyclobutanyl, dihydronaphthyl, tetrahydronaphthyl,naphthyl, decahydronaphthyl, benzocycloheptanyl and benzocycloheptenyl.Certain terms for cycloalkyl such as cyclobutanyl and cyclobutyl shallbe used interchangeably.

The term “heterocycle” refers to a stable nonaromatic 4-8 membered (butpreferably, 5 or 6 membered) monocyclic or nonaromatic 8-11 memberedbicyclic heterocycle radical which may be either saturated orunsaturated. Each heterocycle consists of carbon atoms and one or more,preferably from 1 to 4 heteroatoms chosen from nitrogen, oxygen andsulfur. The heterocycle may be attached by any atom of the cycle, whichresults in the creation of a stable structure.

Unless otherwise stated, heterocycles include but are not limited to,for example pyrrolidinyl, pyrrolinyl, morpholinyl, thiomorpholinyl,thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, dioxalanyl,piperidinyl, piperazinyl, tetrahydrofuranyl, tetrahydropyranyl,tetrahydrofuranyl, 1,3-dioxolanone, 1,3-dioxanone, 1,4-dioxanyl,piperidinonyl, tetrahydropyrimidonyl, pentamethylene sulfide,pentamethylene sulfoxide, pentamethylene sulfone, tetramethylenesulfide, tetramethylene sulfoxide and tetramethylene sulfone.

The term “heteroaryl” shall be understood to mean an aromatic 5-8membered monocyclic or 8-11 membered bicyclic ring containing 1-4heteroatoms such as N, O and S. Unless otherwise stated, suchheteroaryls include thienyl, furanyl, isoxazolyl, oxazolyl, thiazolyl,thiadiazolyl, tetrazolyl, pyrazolyl, pyrrolyl, imidazolyl, pyridinyl,pyrimidinyl, pyrazinyl, pyridazinyl, pyranyl, quinoxalinyl, indolyl,benzimidazolyl, benzoxazolyl, benzothiazolyl, benzothienyl, quinolinyl,quinazolinyl, naphthyridinyl, indazolyl, triazolyl,pyrazolo[3,4-b]pyrimidinyl, purinyl, pyrrolo[2,3-b]pyridinyl,pyrazolo[3,4-b]pyridinyl, tubercidinyl, oxazo[4,5-b]pyridinyl andimidazo[4,5-b]pyridinyl.

The term “heteroatom” used herein shall be understood to mean atomsother than carbon such as O, N, S and P.

In all alkyl groups or carbon chains one or more carbon atoms can beoptionally replaced by heteroatoms: O, S or N, it shall be understoodthat if N is not substituted then it is NH, it shall also be understoodthat the heteroatoms may replace either terminal carbon atoms orinternal carbon atoms within a branched or unbranched carbon chain. Suchgroups can be substituted as herein above described by groups such asoxo to result in definitions such as but not limited to: alkoxycarbonyl,acyl, amido and thioxo.

The term “aryl” as used herein shall be understood to mean aromaticcarbocycle, such as phenyl or naphthyl or heteroaryl as defined above.Each aryl or heteroaryl unless otherwise specified includes it'spartially or fully hydrogenated derivative. For example, quinolinyl mayinclude decahydroquinolinyl and tetrahydroquinolinyl, naphthyl mayinclude it's hydrogenated derivatives such as tetrahydronaphthyl. Otherpartially or fully hydrogenated derivatives of the aryl and heteroarylcompounds described herein will be apparent to one of ordinary skill inthe art.

As used herein, “nitrogen” and “sulfur” include any oxidized form ofnitrogen and sulfur and the quaternized form of any basic nitrogen. Forexample, for an —S—C₁₋₆alkyl radical, unless otherwise specified, thisshall be understood to include —S(O)—C₁₋₆alkyl and —S(O)₂—C₁₋₆ alkyl,likewise, —S—R_(a) may be represented as phenyl-S(O)_(m)— when R_(a) isphenyl and where m is 0, 1 or 2.

The term “halogen” as used in the present specification shall beunderstood to mean bromine, chlorine, fluorine or iodine, preferablyfluorine or chlorine. The definitions “partially or fully halogenated”;partially or fully fluorinated; “substituted by one or more halogenatoms”, includes for example, mono, di or tri halo derivatives on one ormore carbon atoms. For alkyl, a nonlimiting example would be —CH₂CHF₂,—CF₃ etc.

The compounds of the invention ate only those which are contemplated tobe ‘chemically stable’ as will be appreciated by those skilled in theart. For example, a compound which would have a ‘dangling valency’, or a‘carbanion’ are not compounds contemplated by the inventive methodsdisclosed herein.

In another aspect of the invention, the compounds of the invention areformulated into pharmaceutical compositions comprising an effectiveamount, preferably a pharmaceutically effective amount of a compound ofthe invention or a tautomer, or salt thereof and a pharmaceuticallyacceptable excipient or carrier. Pharmaceutically acceptable salts arepreferred.

The invention also provides a kit for the in vitro diagnosticdetermination of Rho kinase function in a sample, comprising: (a) adiagnostically effective amount of a compound according to the inventionor a tautomer thereof, or salt thereof; and (b) instructions for use ofthe diagnostic kit.

The invention includes pharmaceutically acceptable derivatives ofcompounds of formula (I). A “pharmaceutically acceptable derivative”refers to any pharmaceutically acceptable salt or ester, or any othercompound which, upon administration to an individual, is capable ofproviding (directly or indirectly) a compound useful for the invention,or a pharmacologically active metabolite or pharmacologically activeresidue thereof. A pharmacologically active metabolite shall beunderstood to mean any compound of the invention capable of beingmetabolized enzymatically or chemically. This includes, for example,hydroxylated or oxidized derivative compounds of the formula (I).

Pharmaceutically acceptable salts include those derived frompharmaceutically acceptable inorganic and organic acids and bases.Examples of suitable acids include hydrochloric, hydrobromic, sulfuric,nitric, perchloric, fumaric, maleic, phosphoric, glycolic, lactic,salicylic, succinic, toluene-p-sulfonic, tartaric, acetic, citric,methanesulfonic, formic, benzoic, malonic, naphthalene-2-sulfonic andbenzenesulfonic acids. Other acids, such as oxalic acid, while notthemselves pharmaceutically acceptable, may be employed in thepreparation of salts useful as intermediates in obtaining the compoundsand their pharmaceutically acceptable acid addition salts. Salts derivedfrom appropriate bases include alkali metal (e.g., sodium), alkalineearth metal (e.g., magnesium), ammonium and N—(C₁-C₄ alkyl)₄ ⁺ salts.

In addition, within the scope of the invention is use of prodrugs ofcompounds of the formula (I). Prodrugs include those compounds that,upon simple chemical transformation, are modified to produce compoundsof the invention. Simple chemical transformations include hydrolysis,oxidation and reduction. Specifically, when a prodrug is administered toan individual, the prodrug may be transformed into a compound disclosedhereinabove, thereby imparting the desired pharmacological effect.

General Synthetic Methods

The invention additionally provides for methods for making the compoundsof the formula (I). The compounds of the invention may be prepared bythe general methods and examples presented below, and methods known tothose of ordinary skill in the art. Optimum reaction conditions andreaction times may vary depending on the particular reactants used.Unless otherwise specified, solvents, temperatures, pressures, and otherreaction conditions may be readily selected by one of ordinary skill inthe art. Specific procedures are provided in the Synthetic Examplessection. Reaction progress may be monitored by conventional methods suchas thin layer chromatography (TLC). Intermediates and products may bepurified by methods known in the art, including column chromatography,HPLC or recrystallization.

The isoquinolinone core structures used to prepare compounds of formula(I) having ×=C may be prepared by methods known in the art (for example.F. Eloy and A. Deryckere, J. Heterocyclic Chem, 1971, 8, 57; N. Briet etal., Tetrahedron, 2002, 58, 5761) and outlined in Scheme 1.

A nitro substituted cinnamic acid (II) is reduced to the correspondingamine using for example tin II chloride in hydrochloric acid. The amineis protected with a protecting group compatible with the cyclizationconditions, such as an acetyl group. The resulting amide substitutedcinnamic acid (III) is converted to the corresponding acyl azide bymethods known in the art, for example, activation of the carboxylic acidby treatment with a chloroformate such as ethyl chloroformate, in thepresence of an amine such as triethylamine, followed by treatment of theresulting mixed anhydride with an aqueous solution of an azide such assodium azide. The resulting acyl azide (IV) is converted to theisoquinolone by heating in a solvent such as an ether of diethyleneglycol, such as diethylene glycol dibutyl ether (dibutyl carbitol) ordiphenyl ether, preferably in the presence of a base such as tributylamine, at a temperature of 200-300° C., preferably 230-260° C. In somecases, depending on the nature of R₁, a mixture of regioisomericproducts is formed, (Va and Vb) which can be separated bychromatography.

The protecting group may be removed from the separated 6-amino isomer byhydrolysis, preferably under acidic conditions using an acid such asconcentrated hydrochloric acid. The resulting amino isoquinolinoneformed (VI) can be used to prepare amide derivatives of formula (I)(X═C, Y═—NHC(O)—) by coupling with a carboxylic acid or carboxylic acidderivative using methods well known in the art and described in theSynthetic Examples section below. Ureas (X═C, Y═—NHC(O)NH—) andcarbamates (X═C, Y═—NHC(O)O—) may be prepared by reaction of theisoquinolinome VI with an isocyanate or chloroformate respectively.

Quinazolinone intermediates (IX) used to prepare compounds of formula(I) having X.dbd.N may be prepared by methods known in the art asdescribed in Scheme 2.

Heating the nitro anthranilic acid (VII) with a salt of formamidine,preferably the hydrochloride or acetate salt, at a temperature of about200° C., provides VIII (Q. Chao et al., J. Med. Chem. 1999, 42, 3860).Alternatively, the anthranilic acid may be heated with formamide at atemperature of 130 to 150° C. in a microwave reactor (F.-R. Alexandre etal., Tet. Lett. 2002, 43, 3911, and F.-R. Alexandre et al., Tet. Lett.2003, 44, 4455) to provide VIII. Reduction of the nitro group to theamine (IX) may be carried out by standard methods, such as catalytichydrogenation over palladium, or transfer hydrogenation using apalladium catalyst and ammonium formate as the hydrogen source. Theresulting amino quinazolinone formed (IX) can be used to prepare amidederivatives of formula (I) (X═N, Y═—NHC(O)—) by coupling with acarboxylic acid or carboxylic acid derivative) using methods well knownin the art and described in the Synthetic Examples section below. Ureas(X═N, Y═—NHC(O)NH—) and carbamates (X═C, Y═—NHC(O)O—) may be prepared byreaction of the isoquinolinome VI with an isocyanate or chloroformaterespectively.

SYNTHETIC EXAMPLES

Examples 1-7 illustrate the synthesis of 6-aminoisoquinolin-1-one and7-aminoquinazolin-4-one intermediates that may be used to preparedesired compounds of formula (I).

Example 1: Synthesis of 6-aminoisoquinolin-1-one

Tin II chloride dihydrate (1.70 g, 0.75 mol) was dissolved inconcentrated HCl (200 mL). Warming was necessary to obtain a clearsolution. 3-Nitrocinnamic acid (35 g, 0.181 mol) was added portionwisewith stirring. After about 20% of the 3-nitrocinnamic acid had beenadded, the mixture was warmed with a heat gun to 45° C. to initiatereaction. The rate of addition was controlled to maintain a temperatureof 65-75° C. The reaction was exothermic, but not vigorous on thisscale. After the addition was complete, and the reaction started tosubside, the flask was transferred to an oil bath at 65° C. for 1 h. Themixture was then cooled to room temperature. The solid was filtered,washed with 2 N HCl, (100 mL) and sucked dry. The filter cake was driedin a vacuum oven for 1 h, then in air overnight, to give about 65 g ofthe crude amine. This material was suspended in acetic acid (300 mL) andacetic anhydride (150 mL, 1.6 mol) was added gradually with stirring.After the initial exotherm subsided, the mixture was stirred in an oilbath at 110° C. for 2 h, resulting in a clear solution. LCMS showedcomplete conversion to the desired acetanilide. The solution was cooledand water (50 mL) was added. After standing overnight the solution wasconcentrated to about 300 mL. More water (100 mL) and 2 N HCl (50 mL)were added. The precipitate was filtered, washed with water and dried togive 3-acetamido cinnamic acid (33.2 g, 89%).

A solution of 3-acetamido cinnamic acid (3.0 g, 15 mmol) andtriethylamine (4.2 mL, 30 mmol) in acetone (27 mL) was cooled in an icebath. Ethyl chloroformate (1.86 mL, 19.5 mmol) was added, and thesolution was stirred in ice for 40 min. Triethylamine hydrochlorideprecipitated. A solution of sodium azide (1.46 g, 22.5 mmol) in water (3mL) was added. The mixture was stirred in ice for 40 min, then for 1 hat room temperature. Water (15 mL) was added, and the solution wasextracted three times with dichloromethane. The combined organic layerswere dried over magnesium sulfate and evaporated to dryness to give thecrystalline azide.

While this reaction was in progress, a 100 mL 3-neck round bottom flask,equipped with magnetic stirrer, pressure-equalizing addition funnel,thermocouple connected to a J-KEM controller and an air condenser toppedby short-path distillation head and receiver, was charged with a mixtureof diethyleneglycol dibutyl ether (dibutyl carbitol) (10 mL) andtributyl amine (3.3 mL, 15 mmol). The stirred solution was heated to240° C. using a heating mantle connected to the J-KEM controller.Nitrogen was passed through the apparatus via an inlet connected to thetop of the addition funnel. The azide was redissolved in dichloromethane(80 mL, with warming), and this solution was placed in the additionfunnel. The nitrogen stream was stopped. The azide solution was addedslowly dropwise, to maintain the temperature between 230° C. and 240° C.Very vigorous gas evolution occurred as the azide was added. Thedichloromethane boiled off as the solution was added. The addition took2 h 10 min, during which time a distillate collected in the receiver,which was a mixture of dichloromethane and dibutyl carbitol.Periodically during the addition, the receiver was changed. Thedichloromethane was evaporated, and the liquid remaining in the flaskwas returned to the reaction vessel. After the addition was complete,the temperature was maintained at 240° C. for 40 min. The healing mantlewas removed. A dark solid had deposited on the walls of the flask. Oncooling, a crystalline precipitate formed. The precipitate was collectedby filtration, and washed with ether. The dark solid remained in theflask. More solid crystallized from the ether filtrate on standing. Thesupernatant was decanted, and the solid combined with the filteredprecipitate. The supernatant was distilled under high vacuum, to removethe carbitol and tributylamine. The combined solids and pot residue fromthe distillation contained both the 8-acetamido isoquinolin-1-one and6-acetamido isoquinolin-1-one. This material was purified bychromatography on silica, using a dichloromethane/methanol gradient from2% to 15%. The first eluted component was the 8-acetamido isomer (700 mgisolated pure). The second eluted component was the desired 6-acetamidoisomer (600 mg). This component contained impurities, which were removedby triturating the material with a little methanol (ca. 3 mL). Thecrystals were filtered, washed with a few drops of methanol and dried togive pure 6-acetamido isoquinolin-1-one (354 mg, 12%).

A stirred suspension of 6-acetamidoisoquinolin-1-one (1.62 g, 8.0 mmol)in 6 M HCl (60 mL) was healed in an oil bath at 65° C. with stirring.After 2 h a clear solution was obtained, and the reaction was completeby LCMS. The solution was cooled and evaporated almost to dryness.

Methanol was evaporated from residue to leave the hydrochloride salt asa crystalline solid. The salt was suspended in water (40 mL) and heatedto at 60° C. to dissolve. To the resulting solution at 60° C., ammoniumhydroxide was added dropwise, immediately forming a precipitate. Themixture was cooled in ice, the crystals filtered, and washed with water,and finally with a few drops of methanol, which removed some browncolor. The crystals were dried to give the title compound (1.00 g, 78%).

Example 2: Synthesis of 6-amino-5-chloroisoquinolin-1-one

Tin II chloride dihydrate (103 g, 0.46 mol) was dissolved inconcentrated HCl (120 mL). Warming was necessary to obtain a clearsolution. 4-Chloro-3-nitrocinnamic acid (25 g, 0.11 mol) was addedportionwise with stirring. After about 20% of the starting material hadbeen added, the mixture was warmed with a heat gun to 45° C. to initiatereaction. The rate of addition was controlled to maintain a temperatureof 65-75° C. Cooling with a water bath was used to prevent thetemperature exceeding 80° C. After the addition was complete andreaction started to subside, the mixture was transferred to an oil bathat 65° C. for 1 h. The mixture was cooled to room temperature. The solidwas filtered, washed with 2 M HCl, (60 mL) and sucked dry. The filtercake was dried in a vacuum oven for 1 h, then in air overnight, to giveabout 34 g crude product. This material was suspended in acetic acid(100 ml) with stirring and acetic anhydride (100 mL, 1.1 mol) was addedin one portion. The temperature rose to 35° C. After the initialexotherm subsided, the mixture was stirred in an oil bath at 110° C. for2 h, but did not dissolve. LCMS showed complete conversion to thedesired acetanilide. The solution was cooled and water (50 mL) was addedcautiously. The mixture was concentrated to about 200 mL. More water(100 mL) and 2 M HCl (50 mL) were added. The precipitate was filtered,washed with water and dried to give 3-acetamido-4-chlorocinnamic acid(25.0 g, 95%).

A suspension of 3-acetamido-4-chlorocinnamic acid (7.19 g, 30 mmol) andtriethylamine (8.4 mL, 60 mmol) in acetone (100 mL) was cooled in an icebath. Ethyl chloroformate (3.73 mL, 39 mmol) was added, and the solutionwas stirred in ice for 40 min. The acid dissolved and a precipitateformed. A solution of sodium azide (2.93 g, 45 mmol) in water (10 mL)was added. The mixture was stirred in ice for 40 min, then for 1 h atroom temperature. Water (75 mL) was added, and the solution wasextracted three times with dichloromethane. The combined organic layerswere dried over magnesium sulfate and evaporated to dryness, to give thecrystalline azide.

While this reaction was in progress, the apparatus described above inExample 1 was assembled, using a 250 mL 3-neck round bottom flask, whichwas charged with diethyleneglycol dibutyl ether (dibutyl carbitol) (75mL) and tributyl amine (7.2 mL, 30 mmol). The stirred solution washeated to 240° C. using a heating mantle connected to the J-KEMcontroller. Nitrogen was passed through the apparatus via an inletconnected to the top of the addition funnel. The azide was redissolvedin dichloromethane (160 mL), with warming, and this solution was placedin the addition funnel. The nitrogen stream was stopped. The azidesolution was added dropwise, to maintain temp between 230° C. and 250°C., so that the dichloromethane boiled off as the solution was added.The addition took 1 h 40 min. A distillate collected in the receiver,which was a mixture of dichloromethane and dibutyl carbitol.Periodically during the addition, the receiver was changed. Thedichloromethane was evaporated, and the liquid remaining in the flaskwas returned to the reaction vessel. After the addition was complete,the temperature was maintained at 240° C. for 30 min. The heating mantlewas removed. On cooling, a crystalline precipitate formed. The cooledsolution was diluted with ether (150 mL) and stirred overnight. Theprecipitate was collected by filtration, washed well with ether, thenwith a few drops of MeOH, which removed some dark color. The resultingoff-white solid was dried at 60° C. under vacuum to give6-acetamido-5-chloroisoquinoline-1-one (3.1 g). This material containeda minor component which was not removed at this stage.

A stirred suspension of 6-acetamido-5-chloroisoquinolin-1-one (1.4 g,5.9 mmol) in concentrated HCl (50 mL) was heated in an oil bath at65.degree. C. with stirring. After 1 h, a clear solution was obtained,and the reaction was complete by LCMS. The solution was cooled andevaporated almost to dryness. Methanol was evaporated from the residueto leave the hydrochloride salt as a crystalline solid. The salt wasdissolved in methanol and treated with excess ammonium hydroxide to formthe free base. The solution was evaporated to dryness and was purifiedby chromatography on a Combiflash system, using adichloromethane/methanol gradient from 2% to 10%. The major, secondeluting, spot was collected to yield the title compound (883 mg, 72%).

Analogous procedures were used to make the 7-H, 7-bromo, 7-fluoro, and7-trifluoromethyl derivatives using commercially available startingmaterials. The 7-cyano and 7-methoxy analogs were made by the followingmethods below.

Example 3: Synthesis of 6-amino-7-cyano isoquinolin-1-one

A reaction vial was charged with 7-bromo-6-aminoisoquinolonehydrochloride (203 mg, 0.74 mmol), Zn(CN)₂ (155 mmol) and Pd(Ph₃P)₄(0.37 mmol) in 1.5 mL of dry dimethylacetamide. The vial was sealed andwarmed to 100° C. for 20 minutes in a microwave. The reaction wasrecharged with additional Pd(Ph₃P)₄ (0.37 mmol) and warmed for another20 minutes. The reaction was then diluted with 1 N aqueous NaOH and theresulting solids were isolated by filtration (615 mg). The desiredproduct was present in both the solids as well as the filtrate. Thesolids were purified by suspension in dimethylacetamide, filtration toremove insoluble material and reverse phase HPLC chromatography of thefiltrate to afford the desired product as a white solid (62 mg, 46%).The aqueous filtrate from above was neutralized with 1 N aqueous HCl andthe resulting crude product was isolated by filtration (233 mg). Thisadditional material was used without further purification.

Example 4: Synthesis of 6-Amino-7-methoxy isoquinolin-1-one

To a solution of 3-methoxy-4-nitrobenzoic acid (10.00 g, 50.72 mmol) inCH₂Cl₂ (250 mL) was added pyridine (4.89 mL, 60.87 mmol) followed bySOCl₂ (4.06 mL, 55.80 mmol). The reaction was stirred for 5 min thenvolatiles were removed in vacuo. The crude was dissolved in CH₂Cl₂ (200mL) and a solution of triethylamine (8.72 mL, 60.87 mmol) andaminoacetaldehyde dimethyl acetal (6.40 g, 60.87 mmol) in CH₂Cl₂ (50 mL)was added via syringe. The mixture was stirred for 5 min then dilutedwith CH₂Cl₂ (250 mL), washed with saturated aqueous NaHCO₃ (2.times.200mL), dried with MgSO₄, filtered, and concentrated to afford the crudeproduct (14.0 g) which was used as is in the next transformation.

A solution of the above nitro compound (14.0 g) and 20% Pd(OH)₂ oncarbon (1.8 g) was dissolved in MeOH (150 mL). A balloon filled withhydrogen was attached and the system was purged and evacuated (3×). Thesuspension was allowed to stir for 20 h then was filtered through a padof diatomaceous earth. The filtrate was concentrated in vacuo to affordthe desired aniline intermediate as a gold foam (12.25 g, 98%). MS (ES+)m/e 255 [M+H]⁺.

A solution of the aniline (11.00 g, 43.26 mmol) in concentrated H₂SO4(100 mL) was stirred at 100° C. for 1 h. The mixture was cooled to 0° C.and carefully treated with 6 M NaOH to pH=10. The aqueous mixture wasextracted with EtOAc (5×300 mL), dried with MgSO₄, filtered, andconcentrated to give a crude beige solid that was purified by suspendingin CH₂Cl₂ (50 mL) and filtering the solid. The solid was dried to givethe desired 6-amino-7-methoxy-isoquinolin-1-one (1.55 g, 19%). MS (ES+)m/e 191 [M+H]⁺.

Example 5: Synthesis of 6-amino-5-chloro isoquinolin-1-one

To a solution of 0.500 g (3.12 mmol) of 6-amino-2H-isoquinolin-1-one inDMF (30 mL) was added 0.45 g (3.4 mol) of N-chlorosuccinimide. Themixture was stirred at room temperature for 15 h then poured over iceand stirred until all the ice was melted during which time a solidprecipitated from solution. The tan solid was collected by filtration,washed with water and dried on the filter pad to provide 0.50 g (82%yield) of the title compound. MS calc. for C₉H₈ClN₂O [M+H]⁺; 195.63.Found: 195.23.

Example 7: Synthesis or 6-amino-7-chloro-5-fluoro-isoquinolin-1-one

To 20.0 mL (215 mmol) of phosphorous oxychloride, cooled to 0° C., wasadded 5.00 g (25.7 mmol) of 6-amino-7-chloro-2H-isoquinolin-1-one inportions. The mixture was heated to 100° C. for 3 h then cooled to roomtemperature and poured over ice. After all of the ice had melted the pHof the mixture was adjusted to slightly alkaline by the slow addition ofa 10% aqueous NaOH solution. A yellow solid precipitated from solutionand was collected by filtration, washed with water and dried overanhydrous Na₂SO₄ to provide 3.0 g (55%) of1,7-dichloro-isoquinolin-6-ylamine. MS calc. for C₉H₇Cl₂N₂[M+H]⁺:214.08. Found: 213.23 and 215.23.

To a solution of 2.62 g (12.3 mmol) of1,7-dichloro-isoquinolin-6-ylamine in DMF (130 mL) was added 5.5 g (15.5mmol) of Selectfluor® as a solid in one portion. The mixture was stirredat room temperature for 15 h. The mixture was poured over ice andstirred until all of the ice had melted during which time a solidprecipitated from solution. The brown solid was collected by filtration,washed with water and dried on the filter pad to provide 1.0 g (60% by.sup.1H-NMR, 21%) of 1,7-dichloro-5-fluoro-isoquinolin-6-ylamine. MScalc. for C₉H₅Cl₂FN₂ [M]⁺: 231.05. Found: 231.68.

A mixture of 1.0 g (4.3 mmol) of the above crude intermediate in 50 mL(100 mmol) of a 2 N solution of hydrochloric acid was heated at 100° C.for 15 h then cooled to room temperature. The pH of the solution wasadjusted to slightly alkaline by the addition of a 10% NaOH solution. Asolid precipitated from solution and was collected by filtration anddried on the filter pad. The residue was purified by flash silica gelchromatography using a 0-50% gradient of MeCN to hexanes to provide 0.15g (16%) of the title compound. MS calc. for C₉H₇ClFN₂O [M+H]⁺: 213.62.Found: 213.42.

Example 8: Synthesis of 7-aminoquinazolin-4-one

4-Nitroanthranilic acid (10.0 g. 54.9 mmol) and formamidinehydrochloride (6.63 g, 82.4 mmol) were ground together in a mortar andpestle to produce a fine, intimate mixture. The mixture was placed in a250 mL round-bottom flask, and spread evenly over the surface. The flaskwas placed in an oil bath at 200° C. The solid underwent a color change,and a distillate was seen on the side of flask, but did not really melt.After 30 min the flask was removed from the heating bath. 0.3M sodiumhydroxide solution (150 mL) was added to the cooled flask, the blacksolid mass was broken up with a spatula, and stirred for 1 h. The solidwas filtered off and washed with water. The filtrate was discarded. Theblack solid was suspended in dichloromethane/methanol (10:1) andfiltered through a plug of silica, eluting with the same solvent untilno more product came off. The material was one spot by TLC, plus blackbaseline material, but was poorly soluble, so a large volume of solventwas needed. The filtrate was evaporated to dryness and the solid residuetriturated with a little methanol and filtered to give7-nitroquinazolin-4-one (4.65 g, 44%).

A suspension of 7-nitroquinazolinone (5.2 g, 22.7 mmol) in DMF (150 mL)and methanol (100 mL) was hydrogenated over 10% palladium on carbon (600mg) in a Parr shaker at 50 psi. The starting material was consumed in 3h, but hydrogenation was continued for 18 h to ensure complete reaction.The mixture was filtered through diatomaceous earth, washing withmethanol/DMF 2:1 until all of the product was eluted. The filtrate wasevaporated to dryness. The solid residue was stirred with methanol (20mL) for 1 h, filtered, washed with methanol and dried to give the crudeamine (3.88 g), which contained a minor component (ca. 10%). The crudeproduct was dissolved in 2 N HCl (100 mL), with warming, and theresulting solution was evaporated to dryness to give the hydrochloridesalt. The salt was dissolved in boiling water (30 mL) and ethanol (30mL) was added. The solvent was boiled down to 50 mL. The hydrochloridecrystallized on cooling. The crystals were filtered, washed with alittle ethanol and dried to give the pure salt (3.02 g). The salt wasdissolved in water (30 mL) with warming to 65° C. in an oil bath.Ammonium hydroxide was added dropwise, causing immediate precipitationof the free base. The flask was cooled in ice, the crystals filtered,washed with water and dried to give the title compound (2.35 g, 54%).

Example 9: Synthesis of 6-Chloro-7-aminoquinazolin-4-one

Methanol (500 mL) and concentrated H₂SO₄ (25 mL) were added to4-nitroanthranilic acid (30.0 g, 165.0 mmol) and the reaction mixturewas heated at reflux for 48 h. The resulting solution was concentratedand saturated NaHCO₃ (200 mL) was added. The aqueous layer was extractedwith EtOAc (2.times.150 mL). The combined organic extracts were washedwith water (100 mL), and brine (100 mL), dried over Na₂SO, filtered, andconcentrated to give the methyl ester (29.0 g, 90%) as an intense orangesolid.

To a suspension of 4-nitroanthranilic acid methyl ester (16.5 g, 84mmol) in glacial acetic acid (500 mL), a solution of sulfuryl chloride(13.6 g, 0.1 mol) in glacial acetic acid (20 mL) was added dropwise. Thehomogeneous mixture was stirred at room temperature for 18 h and thesolvent was evaporated in vacuo. The residue was dissolved in CH₂Cl₂(200 mL) and washed with saturated NaHCO₃ (100 mL) and water (100 mL).The organic layer was dried over Na₂SO₄, filtered, and concentrated. The¹H NMR spectrum of the crude compound revealed the formation of amixture of products, namely the desired 5-chloro regioisomer, and thebyproducts 3-chloro regioisomer and the 3,5-dichlorinated compound. Thecrude mixture was purified by flush chromatography (silica gel, gradient30-100% hexanes/CH₂Cl₂) to afford the desired5-Chloro-4-nitroanthranilic acid methyl ester (7.1 g, 36%) as a paleyellow solid.

To a solution of 5-chloro-4-nitroanthranilic acid methyl ester (10.0 g,43 mmol) in THF (120 mL) was added LiOH (2.7 g, 65 mmol) dissolved inwater (40 mL). The reaction mixture was stirred at room temperature for18 h and acidified to pH .about.4 with 1 N HCl. The aqueous layer wasextracted with EtOAc (2.times.150 mL); the combined organic layers weredried over Na₂SO₄, filtered, and concentrated to give5-chloro-4-nitroanthranilic acid (8.7 g, 88%) as an orange solid.

A mixture of 5-chloro-4-nitroanthranilic acid (8.7 g, 0.040 mol) andformamidine hydrochloride (4.9 g, 60 mmol) were ground to a fine,intimate powder using a mortar and pestle. The mixture was transferredinto a 250 mL round bottomed flask and immersed in an oil bathmaintained at 205° C. After 40 min, LCMS analysis of the reactionmixture showed mass corresponding to the product. The reaction mixturewas cooled and the crude product was crushed into pieces and washedseveral times with saturated NaHCO₃ (300 mL) and water (200 mL). Thesolid was air dried and triturated with a minimum amount of MeOH (20 mL)to obtain 6-chloro-7-nitroquinazolin-4-one (7.6 g, 83%) as a tan powder.

To a suspension of 6-chloro-7-nitroquinazolin-4-one (7.5 g, 33 mmol) inMeOH (250 mL) was added NH₄Cl (17.7 g, 0.33 mol) dissolved in water (75mL). Iron powder (18.5 g, 330 mmol) was added and the suspension washeated at 65° C. for 2 h. The warm reaction mixture was filtered overdiatomaceous earth and washed several times with THF (1 L) and methanol(500 mL). The filtrate was concentrated, washed with water and driedunder vacuum at 50° C. to afford the title compound (6.5 g, 90%) as abrown solid. ESI-MS m/z 196 [C₈H₆ClN₃O+H]⁺.

Example 10: Parallel Synthesis of Amides of Formula (I). Method 1

Intermediates from Examples 1-4 were acylated with a variety of acidchlorides as follows: Acid chlorides were dissolved in dimethylacetamide(DMA) to give a 0.67 mM solution. The amine intermediates were dissolvedin DMA to give a 0.171 mM solution. 150 microL (100 micromol) of acidchloride solution was transferred to each well of a deep-well microtitreplate. 350 microL (60 micromol) of the appropriate amine solution wasadded to each well. The plate was sealed and placed on a shaker for 24h. Silica-bound amine scavenger (about 50 mg) was added to each well,and the plate was shaken for 30 min. Silica-bound carbonate scavenger(about 125 mg) was added to each well, and the plates were shaken for afurther 20 h. The contents of the plate were transferred to a filterplate and filtered into a fresh deep-well plate. The scavenger waswashed with two 400 microL portions of DMA. Aliquots were removed fromeach well for LCMS analysis. The solutions were evaporated in a Genevac.The purity was assessed by UV at 240 nm. Samples below 80% purity werepurified by preparative HPLC.

Example 11: Synthesis ofN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclopropylamino-2-phen-yl-acetamide.Method 2

7-Chloro, 6-aminoisoquinolone (25 mg, 0.13 mmol) was dissolved in DMF.2-Chlorophenylacetyl chloride (1.2 eq, 22 microL, 0.15 mmol) was addedfollowed by diisopropylethylamine (2 eq., 45 microL, 0.26 mmol). Thereaction mixture was shaken for 3 hr on a reaction block at 75° C. Thiscrude mixture was carried on to the next step without purification.

The crude reaction mixture from the previous step was taken as is andexcess cyclopropylamine (100 microL, 11 eq.) was added. The reactionmixture was shaken on a reaction block for 16 hr at 75° C. This crudereaction mixture was purified directly as is on preparative LC-MS.N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclopropylamino-2-phen-yl-acetamide(21 mg, 0.05 mmol) was isolated as an amorphous solid in 40% yield.ES+=368.

Example 12: Synthesis of2-amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-phenyl-propionamide.Method 3

6-Amino-7-chloro-2H-isoquinolin-1-one (0.2 mmol, 39 mg) andL-Fmoc-2-amino-3-phenyl-propionyl chloride (0.2 mmol, 81 mg) weredissolved in 3 mL DMF. The mixture was allowed to stir at roomovernight. HPLC-MS confirmed the product had formed. The crude productwas carried on to the next step without further purification. MS (M+1)565.

The above crude product in DMF was treated with piperidine (5-10% totalconcentration), and the reaction mixture was allowed to stir at roomovernight. The title compound was obtained after prep-HPLC purification.MS (M+1) 342.

Example 13: Synthesis of1-benzyl-3-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-urea. Method 4

6-Amino-2H-isoquinolin-1-one (0.2 mmol, 39 mg) and benzyl isocyanate(0.2 mmol, 27 mg) were dissolved in 1 mL DMA. The mixture was allowed tostir at 60° C. overnight. The product was obtained by HPLC purification.MS (M+1) 294.

Example 14: Synthesis of 4-(4-chloro-phenyl)-pyrrolidine-3-carboxylicacid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide

To a solution of benzyl-methoxymethyl-trimethylsilanylmethyl-amine (2.05mL, 8.0 mmol) and (E)-3-(4-chloro-phenyl)-acrylic acid methyl ester(1.57 g, 8.0 mmol) in dichloromethane (16 mL) was added TFA (275 mg, 2.4mmol). The mixture was stirred at 23° C. for 30 min then treated withsaturated aqueous NaHCO₃ (20 mL), extracted with dichloromethane (2×50mL), dried with MgSO₄, filtered, and concentrated. Purification of thecrude by flash chromatography (SiO₂, hexane to 1:1 hexane:EtOAc) gave(trans)-1-benzyl-4-(4-chloro-phenyl)-pyrrolidine-3-carboxylic acid ethylester (2.11 g, 80%).

A solution of the ester from above (1.01 g, 2.94 mmol) in MeOH (15 mL)and THF (5 mL) was treated with a 6 M aqueous NaOH solution (4.9 mL,29.4 mmol) and heated at reflux for 2 h. The mixture was then acidifiedto pH=1 with 6 M aqueous HCl, extracted with dichloromethane, dried withMgSO₄, filtered, and concentrated to afford1-benzyl-4-(4-chloro-phenyl)-pyrrolidine-3-carboxylic acid as the HClsalt (1.00 g, 97%).

To a solution of the acid from above (1.06 g, 3.0 mmol) and6-amino-5-chloroisoquinolin-1-one (450 mg, 2.3 mmol) in pyridine (5 mL)was added POCl₃ (320 μL, 3.5 mmol). The mixture was stirred for 1 h thentreated with water, extracted with EtOAc, dried with MgSO₄, filtered,and concentrated to afford1-benzyl-4-(4-chloro-phenyl)-pyrrolidine-3-carboxylic acid(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide (454 mg, 40%).

The above N-benzyl pyrrolidine (216 mg, 0.44 mmol) was dissolved indichloroethane (5 mL) and treated with alpha chloroethyl chloroformate(95 microL, 0.88 mmol) followed by proton sponge (69 mg, 0.44 mmol). Themixture was stirred at 23° C. for 1 h then heated at reflux for 3 h. Themixture was then concentrated in vacuo, diluted with MeOH (10 mL), andheated at reflux for 2 h. The solution was concentrated in vacuo thenpurified by RP HPLC to afford the desired product as the TFA salt (88mg, 40%) MS MH+=402.3

The following compounds were also prepared using the methods describedin the General Synthetic Methods section and the synthetic examplesabove:

Name MH+N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2- 357phenyl-acetamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-y1)-2-(4-methyl- 336piperazin-1-yl)-acetamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-y1)-2-(cyclohexylmethyl- 349amino)-acetamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-y1)-2-(4-hydroxy- 413piperidin-1-yl)-2-phenyl-acetamide2-Senzylamino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2- 419phenyl-acetamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-thiomorpholin-4-yl-353 propionamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(1,2,3,4-tetrahydro-383 naphthalen-l-ylamino)-acetamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-y1)-2-(2-thiophen-2-yl- 377ethylamino)-propionamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methylamino-2- 343phenyl-acetamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(ethyl-methyl- 371amino)-2-phenyl-acetamide(S)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-phenyl-343 propionamide(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-phenyl-343 propionamide(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2- 329phenyl-acetamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclobutyl-amino-2-383 phenyl-acetamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(cyclo-propylmethyl-383 amino)-2-phenyl-acetamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(3-ethoxy- 415propylamino)-2-phenyl-acetamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-[(2-dimethylamino- 428ethyl)-ethyl-amino]-2-phenyl-acctamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-[(tetra-hydro-pyran-351 4-ylmethyl)-amino]-acetamide2-(Adamantan-1-ylamino)-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin- 3876-yl)-acetamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-[(pyridin-2- 344ylmethyl)-amino]-acetamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-[(pyridin-3- 344ylmethyl)-amino]-acetamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-[(pyridin-4- 344ylmethyl)-amino]-acetamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(cyclohexyl-methyl-349 amino)-acetamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methylamino- 281propionamide2-Dimethylamino-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide 2462-(Cyclohexylmethyl-amino)-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)- 314acetamide2-Dimethylamino-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenyl- 322acetamide Acetic acid(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-ylcarbamoyl)- 372phenyl-methyl esterN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-hydroxy-2-phenyl- 330acetamide (R)-2-Amino-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenyl-294 acetamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(4-chloro-phenyl)-3-390 methyl-butyramide 2,5-Dichloro-thiophene-3-carboxylic acid(1-oxo-1,2-dihydro- 340 isoquinolin-6-yl)-amideN-(1-Oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenylsulfanyl-nicotinamide 3742-(3-Methoxy-phenyl)-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)- 309acetamide 2-(4-Chloro-phenoxy)-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-393 nicotinamide2-(4-Chloro-phenoxy)-2-methyl-N-(1-oxo-1,2-dihydro-isoquinolin-6- 358yl)-propionamide N-(1-Oxo-1,2-dihydro-isoquinolin-6-yl)-succinamic acidethyl ester 289 Thiophene-2-carboxylic acid(1-oxo-1,2-dihydro-isoquinolin-6-yl)- 271 amide1-(4-Chloro-phenyl)-cyclopentanecarboxylic acid (1-oxo-1,2-dihydro- 368isoquinolin-6-yl)-amide2-(4-Chlorophenoxy)-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)- 330acetamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methyl-benzamide 314N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenyl-acetamide 314N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2,3,6-trifluoro- 354benzamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-5-fluoro-2-methyl- 332benzamide2-Chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-nitro- 379benzamide2-Bromo-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-benzamide 379N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(4-fluoro-phenyl)- 332acetamide N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2,2-dimethyl-280 propionamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3,3-dimethyl- 294butyramideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenylsulfanyl- 409nicotinamide2,4-Dichloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)- 369benzamide 5-Methyl-3-phenyl-isoxazolc-4-carboxylic acid(7-chloro-1-oxo-1,2- 381 dihydro-isoquinolin-6-yl)-amideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2,4,6-trifluoro- 354benzamide 1-(4-Chloro-phenyl)-cyclopentanecarboxylic acid(4-oxo-3,4-dihydro- 368 quinazolin-7-yl)-amide Piperidine-4-carboxylicacid (4-oxo-3,4-dihydro-quinazolin-7-yl)- 273 amide2-Benzylamino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-acetamide 3091-Benzyl-piperidine-4-carboxylic acid (4-oxo-3,4-dihydro-quinazolin- 3b37-yl)-amide Piperidine-3-carboxylic acid(4-oxo-3,4-dihydro-quinazolin-7-yl)- 273 amide Pyrrolidine-2-carboxylicacid (4-oxo-3,4-dihydro-quinazolin-7-yl)- 259 amide2-Amino-4-methyl-pentanoic acid (4-oxo-3,4-dihydro-quinazolin-7-yl)- Z75amide (R)-2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-3-phenyl- 309propionamide (S)-2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-3-phenyl-309 propionamide2-(Cyclohexylmethyl-amino)-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)- 315acetamide 2-Methylamino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-phenyl-309 acetamide2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-phenyl-acctamide 2952-Cyclopropylamino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-phenyl- 335acctamide (R)-2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-phenyl-295 acctamide (R)-Pyrrolidine-2-carboxylic acid(4-oxo-3,4-dihydro-quinazolin-7-yl)- 259 amide(R)-2-Amino-3-methyl-N-(4-oxo-3,4-dihydro-quinazolin-7-y1)- 261butyrarnide2-(Cyclopropylmethyl-amino)-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)- 273acetamideN-(4-Oxo-3,4-dihydro-quinazolin-7-yl)-2-(2-thiophen-2-yl-ethylamino)-329 acctamide2-(Cyclohexyl-methyl-amino)-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)- 315acetamideN-(6-Chloro-4-oxo-3,4-dihydro-quinazolin-7-yl)-2-dimethylamino-2- 357phenyl-acctamideN(6-Chloro-4-oxo-3,4-dihydro-quinazolin-7-yl)-2-cyclopropylamino-2- 369phenyl-acetamide 2,5-Dimethyl-2H-pyrazole-3-carboxylic acid(4-oxo-3,4-dihydro- 284 quinazolin-7-yl)-amide2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-(4-fluoro- 360phenyl)-propionamide(R)-2-Amino-2-cyclohexyl-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)- 300acetamide(R)-2-Amino-2-(4-chloro-phenyl)-N-(1-oxo-1,2-dihydro-isoquinolin-6- 362yl)-acetamide (R)-Pyrrolidine-2-carboxylic acid(7-chloro-1-oxo-1,2-dihydro- 292 isoquinolin-6-yl)-amide(S)-Pyrrolidine-2-carboxylic acid (7-chloro-1-oxo-1,2-dihydro- 292isoquinolin-6-yl)-amide2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-acetamide 252Piperidine-4-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-isoquinolin-306 6-yl)-amide,(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-(4- 376chloro-phenyl)-propionamide(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-p-tolyl-342 acetamide(S)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3- 348cyclohexyl-propionamide(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3- 348cyclohexyl-propionamide (R)-2-Amino-4,4-dimethyl-pentanoic acid(7-chloro-1-oxo-1,2-dihydro- 322 isoquinolin-6-yl)-amide(S)-2-Amino-4,4-dimethyl-pentanoic acid (7-chloro-1-oxo-1,2-dihydro- 322isoquinolin-6-yl)-amide2-Chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4- 411methanesulfonyl-benzamide2-Chloro-N(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-rnorpholin-418 4-yl-benzamide(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3- 392naphthalen-2-yl-propionamide(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3- 392naphthalen-1-yl-propionamide(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-pyridin-343 4-yl-propionamide2-Methyl-2-methylamino-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)- 260propionamide 2-Amino-2-methyl-N-(1-oxo-1,2-dihydro-isoquinolin-6-yl)-246 propionamide(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methoxy-2- 343phenyl-acetamide(S)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methoxy-2- 343phenyl-acetamide3-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)- 266propionamide(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-methyl-294 butyramideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3,3,3-trifluoro-2- 411methoxy-2-phenyl-propionamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-oxo-2-phenyl- 327acetamide (R)-Piperidine-2-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-306 isoquinolin-6-yl)-amide2-tert-Butylamino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)- 308acetamide(R)-2-Methoxy-N-(7-methoxy-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2- 339phenyl-acetamide(S)-2-Methoxy-N-(7-methoxy-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2- 339phenyl-acetamide(R)-2-Amino-2-cyclohexyl-N-(7-methoxy-1-oxo-1,2-dihydro- 330isoquinolin-6-yl)-acetamide(S)-2-Amino-2-cyclohexyl-N-(7-methoxy-1-oxo-1,2-dihydro- 330isoquinolin-6-yl)-acetamide4-Bromo-2-chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)- 413benzamide 2-Chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-5-412 methanesulfonyl-benzamide (R)-Tetrahydro-furan-2-carboxylic acid(7-chloro-1-oxo-1,2-dihydro- 293 isoquinolin-6-yl)-amide(S)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-hydroxy-2- 329phenyl-acetamide(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-hydroxy-2- 329phenyl-acetamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyano-benzamide 324N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methy1-4-nitro- 358benzamide N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-nitro-2- 412trifluoromethyl-benzamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-morpholin-4- 398ylmethyl-benzamide 1-Amino-cyclohexanecarboxylic acid(1-oxo-1,2-dihydro-isoquinolin- 286 6-yl)-amide(R)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2- 334cyclohexyl-acetamide (R)-2-Amino-4-methyl-pentanoic acid(7-chloro-1-oxo-1,2-dihydro- 308 isoquinolin-6-yl)-amide(S)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2- 334cyclohexyl-acetamide (S)-2-Amino-4-methyl-pentanoic acid(7-chloro-1-oxo-1,2-dihydro- 308 isoquinolin-6-yl)-amide(S)-2-Amino-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-methyl-294 butyramideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(4-methyl- 411piperazin-1-ylmethyl)-benzamide1,2,3,4-Tetrahydro-isoquinoline-5-carboxylic acid (7-chloro-1-oxo-1,2-354 dihydro-isoquinolin-6-yl)-amide1,2,3,4-Tetrahydro-isoquinoline-8-carboxylic acid (7-chloro-1-oxo-1,2-354 dihydro-isoquinolin-6-yl)-amide 1-Methyl-piperidine-4-carboxylicacid (7-chloro-1-oxo-1,2-dihydro- 320 isoquinolin-6-yl)-amide(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-methyl- 323succinamic acid methyl ester2-Chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-nitro- 378benzamide2-Chloro-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-5-nitro- 378benzamide (S)-Tetrahydro-furan-2-carboxylic acid(7-chloro-1-oxo-1,2-dihydro- 293 isoquinolin-6-yl)-amideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-methylsulfanyl- 297propionamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyano-acetamide 2622-Bromo-N-(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-methyl- 392benzamide Tetrahydro-pyran-4-carboxylic acid(7-chloro-1-oxo-1,2-dihydro- 307 isoquinolin-6-yl)-amideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-3-phenyl-succinamic 371acid N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-malonamic acidethyl 309 esterN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methylsulfanyl- 283acetamide (S)-Pyrrolidine-3-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-292 isoquinolin-6-yl)-amide (S)-Piperidine-3-carboxylic acid(7-chloro-1-oxo-1,2-dihydro- 306 isoquinolin-6-yl)-amide(R)-Piperidine-3-carboxylic acid (7-chloro-1-oxo-1,2-dihydro- 306isoquinolin-6-yl)-amideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methanesulfonyl- 315acetamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenyl-malonamic 357acid (S)-Piperidine-2-carboxylic acid (7-chloro-1-oxo-1,2-dihydro- 306isoquinolin-6-yl)-amide1-Methanesulfony1-4-methyl-piperidine-4-carboxylic acid (7-chloro-1- 398oxo-1,2-dihydro-isoquinolin-6-yl)-amide2-Chloro-N(7-chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-nitro- 378benzamideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-4-methanesulfonyl- 377benzamide (R)-Pyrrolidine-3-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-292 isoquinolin-6-yl)-amide 4-Amino-cyclohexanccarboxylic acid(7-chloro-1-oxo-1,2-dihydro- 320 isoquinolin-6-yl)-amide4-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-ylcarbamoyl)- 349cyclohexanecarboxylic acid(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-isopropoxy-2- 371phenyl-acetamide(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenoxy- 343propionamide(S)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenoxy- 343propionamide 4-Phenyl-piperidine-4-carboxylic acid(7-chloro-l-oxo-1,2-dihydro- 382 isoquinolin-6-yl)-amide4-(4-Chloro-phenyl)-piperidine-4-carboxylic acid (7-chloro-1-oxo-1,2-416 dihydro-isoquinolin-6-yl)-amide 4-Benzyl-piperidine-4-carboxylicacid (7-chloro-1-oxo-1,2-dihydro- 396 isoquinolin-6-yl)-amide(R)-Piperidine-3-carboxylic acid (1-oxo-1,2-dihydro-isoquinolin-6-yl)-272 amide (S)-Piperidine-3-carboxylic acid(1-oxo-1,2-dihydro-isoquinolin-6-yl)- 272 amide1-Methyl-piperidine-4-carboxylic acid (1-oxo-1,2-dihydro-isoquinolin-286 6-yl)-amide(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-hydroxy-3- 295methyl-butyramide Piperazine-2-carboxylic acid(7-chloro-1-oxo-1,2-dihydro-isoquinolin- 307 6-yl)-amide4-Methyl-piperidine-4-carboxylic acid (7-chloro-1-oxo-1,2-dihydro- 320isoquinolin-6-yl)-amide (3S,4S)-3-Methyl-piperidine-4-carboxylic acid(7-chloro-1-oxo-1,2- 306 dihydro-isoquinolin-6-yl)-amide(trans)-4-Phenyl-piperidine-3-carboxylic acid (7-chloro-1-oxo-1,2- 382dihydro-isoquinolin-6-y1)-amide(1R,3S)-3-Amino-cyclopentanecarboxylicacid (7-chloro-1-oxo-1,2- 306dihydro-isoquinolin-6-yl)-amide 4-Hydroxy-cyclohexanecarboxylic acid(7-chloro-1-oxo-1,2-dihydro- 321 isoquinolin-6-yl)-amide(S)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclohexyl-2- 335hydroxy-acetamide(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclohexyl-2- 335hydroxy-acetamide(S)-N(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-hydroxy-2- 343phenyl-propionamide(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-hydroxy-2- 343phenyl-propionamide (1R,3S)-3-Amino-cyclohexanecarboxylic acid(7-chloro-1-oxo-1,2- 320 dihydro-isoquinolin-6-yl)-amide(1R,3S)-3-Amino-cyclohexanecarboxylic acid (7-methoxy-1-oxo-1,2- 316dihydro-isoquinolin-6-yl)-amide (3R,4S)-3-Methyl-piperidine-4-carboxylicacid (7-chloro-1-oxo-1,2- 320 dihydro-isoquinolin-6-yl)-amide4-Dimethylamino-cyclohexanecarboxylic acid (7-chloro-1-oxo-1,2- 348dihydro-isoquinolin-6-yl)-amide Trans-3-amino-cyclobutanecarboxylic acid(7-chloro-1-oxo-1,2- 292 dihydro-isoquinolin-6-yl)-amideCis-3-amino-cyclobutanecarboxylic acid (7-chloro-1-oxo-1,2-dihydro- 292isoquinolin-6-yl)-amide4-Amino-1-(cis-4-chloro-phenyl)-cyclohexanecarboxylic acid (7- 430chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide4-Amino-1-(trans-4-chloro-phenyl)-cyclohexanecarboxylic acid (7- 430chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-amide(S)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclohexyl-2- 391isopropylamino-acetamide(S)-N(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclohexyl-2- 320isopropylamino-acetamide(S)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-cyclohexyl-2- 376isopropylamino-acetamide 4-(4-Fluoro-phenyl)-pyrrolidine-3-carboxylicacid (1-oxo-1,2-dihydro- 352 isoquinolin-6-yl)-amide(1S,2S)-2-Methyl-4-oxo-cyclohexanccarboxylic acid (7-chloro-1-oxo- 3331,2-dihydro-isoquinolin-6-yl)-amide 3-Phenyl-pyrrolidine-3-carboxylicacid (7-chloro-1-oxo-1,2-dihydro- 368 isoquinolin-6-yl)-amide1-Isopropyl-piperidine-4-carboxylic acid (7-chloro-1-oxo-1,2-dihydro-348 isoquinolin-6-yl)-amide 1-Cyclohexyl-piperidine-4-carboxylic acid(7-chloro-1-oxo-1,2- 334 dihydro-isoquinolin-6-yl)-amide1-Cyclohexyl-piperidine-4-carboxylic acid (7-chloro-1-oxo-1,2- 388dihydro-isoquinolin-6-yl)-amideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-mcthyl-4- 397(piperazine-l-sulfonyl)-benzamidcN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methyl-4- 461(piperazine-1-sulfonyl)-benzamide (R)-N(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(2-chloro- 363phenyl)-2-hydroxy-acetamide(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(3-chloro- 363phenyl)-2-hydroxy-acetamide (2S,3R)-2-Amino-3-methyl-pentanoic acid(7-chloro-1-oxo-1,2- 308 dihydro-isoquinolin-6-yl)-amideN-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-phenyl- 341isobutyramide 1-Benzyl-piperidine-4-carboxylic acid(7-chloro-1-oxo-1,2-dihydro- 396 isoquinolin-6-yl)-amide(trans)-4-Phenyl-pyrrolidine-3-carboxylic acid (7-chloro-1-oxo-1,2- 368dihydro-isoquinolin-6-yl)-amide(trans)-4-(4-Fluoro-phenyl)-pyrrolidine-3-carboxylic acid (7-chloro-1-386 oxo-1,2-dihydro-isoquinolin-6-yl)-amide(3R,4S)-1,3-Dimethyl-piperidine-4-carboxylic acid (7-chloro-1-oxo-1,2-334 dihydro-isoquinolin-6-yl)-amide 5-Phenyl-piperidine-3-carboxylicacid (7-chloro-1-oxo-1,2-dihydro- 382 isoquinolin-6-yl)-amide1,2,3,4-Tetrahydro-isoquinoline-7-carboxylic acid (7-chloro-1-oxo-1,2-354 dihydro-isoquinolin-6-yl)-amide1,2,3,4-Tetrahydro-isoquinoline-6-carboxylic acid (7-chloro-1-oxo-1,2-354 dihydro-isoquinolin-6-yl)-amide4-(3-Amino-propane-1-sulfonyl)-2-chloro-N-(7-chloro-1-oxo-1,2- 454dihydro-isoquinolin-6-yl)-benzamide(trans)-4-(3-Bromo-phenyl)-pyrrolidine-3-carboxylic acid (7-chloro-1-447 oxo-1,2-dihydro-isoquinolin-6-yl)-amide(trans)-4-(4-Chloro-phenyl)-pyrrolidine-3-carboxylic acid (7-chloro-1-402 oxo-1,2-dihydro-isoquinolin-6-yl)-amide(1R,5S,6R)-3-Aza-bicyclo[3.1.0]hexane-6-carboxylic acid (7-chloro-1- 304oxo-1,2-dihydro-isoquinolin-6-yl)-amide(1R,5S,6S)-3-Aza-bicyclo[3.1.0]hexane-6-carboxylic acid (7-chloro-1- 304oxo-1,2-dihydro-isoquinolin-6-yl)-amide(trans)-4-(3-Bromo-phenyl)-pyrrolidine-3-carboxylic acid (6-chloro-4-448 oxo-3,4-dihydro-quinazolin-7-yl)-amide(R)-N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-(4-chloro- 377phenyl)-2-hydroxy-propionamide(R)-N-(6-Chloro-4-oxo-3,4-dihydro-quinazolin-7-yl)-2-(4-chloro- 378phenyl)-2-hydroxy-propionamide(R)-2-(4-Chloro-phenyl)-2-hydroxy-N-(4-oxo-3,4-dihydro-quinazolin-7- 344yl)-propionamide 1-Methyl-piperidine-4-carboxylic acid(7-bromo-1-oxo-1,2-dihydro- 365 isoquinolin-6-yl)-amide1-Methyl-piperidine-4-carboxylic acid (7-fluoro-1-oxo-1,2-dihydro- 304isoquinolin-6-yl)-amide 1-Methyl-piperidine-4-carboxylic acid(7-cyano-1-oxo-1,2-dihydro- 311 isoquinolin-6-yl)-amide(trans)-4-Phenyl-pyrrolidine-3-carboxylic acid (7-bromo-1-oxo-1,2- 413dihydro-isoquinolin-6-yl)-amide4-(4-Chlorophenyl)-pyrrolidine-3-carboxylic acid (7-bromo-1-oxo-1,2- 447dihydro-isoquinolin-6-yl)-amide(trans)-4-Phenyl-pyrrolidine-3-carboxylic acid (5-chloro-1-oxo-1,2- 369dihydro-isoquinolin-6-yl)-amide(trans)-4-Phenyl-pyrrolidine-3-carboxylic acid (7-chloro-5-fluoro-1- 386oxo-1,2-dihydro-isoquinolin-6-yl)-amide

Assessment of Biological Activity

Molecular Assay

The activity of ROCKII (1-543) kinase was measured utilizing CambrexPKLight ATP Detection Reagent, a homogeneous assay technology usingluciferin-luciferase to quantify residual ATP. The assay was performedin 384-well low-volume, white, non-binding surface microtiter plates(Corning). The assay buffer was 25 mM HEPES, pH 7.5, 10 mM MgCl₂, 50 mMKCl, 0.2% BSA, 0.01% CHAPS, 100 μM Na₃VO₄ and 0.5 mM DTT. Testcompounds, dissolved in neat DMSO at 500 μg/mL, were serially dilutedfor dose response for a final starting concentration of 3 μg/mL in 1%DMSO of assay buffer. ROCKII (1-543) (62,408 Da) was diluted in assaybuffer to a final concentration of 7.5 nM in a total volume of 15 μL.Positive controls were reaction mixtures containing no test compound;negative controls (blanks) were reaction mixtures containing no kinase.After 15 minutes of pre-incubation of the test compounds with thekinase, a mixture of ATP and peptide substrate (AKRRRLSSLRA) in assaybuffer was added to each well for a final concentration of 750 nM ATPand 500 nM peptide, respectively. After 90 minutes of incubation of thekinase reaction at 28° C. temperature, 10 μL of PKLight ATP DetectionReagent (warmed to room temperature previously) was added to each well.The assay plate was incubated at room temperature for additional 15minutes and then read on an Analyst in luminescence mode. Dose-responseexperiments of each test compounds were conducted in quadruplet. IC₅₀values of test compounds represent 50% response of the positive controlfrom the dose-response curve.

Preferred compounds have an IC₅₀<1 μM in this assay.

Selected compounds were evaluated in a Rat Aortic Rings tissue assay:

Rat Aortic Rings Tissue Assay

Segments of rat thoracic aorta were dissected from Sprague Dawley ratscleaned of excess connective tissue, and cut into 3-4 mm rings in apetri dish filled with 4° C. PBS, containing 118 mM NaCl; 4.7 mM KCl;1.6 mM CaCl₂; 1.2 mM KH₂PO₄; 1.2 mM MgCl₂; 10.0 mM Dextrose; 25 mMNaHCO₃; 0.02 mM NaEDTA; pH 7.25, and kept on ice before dissection. Therings were then suspended on a force transducer device and placed into37° C. temperature-controlled tissue baths containing PBS that wasconstantly oxygenated with 95% O₂ and 5% CO₂. Isometric force wascontinually measured and the data collected by a digital acquisitionsystem. The rings were placed under a preload of 2.5 g of force for a 1hr equilibration period to serve as baseline force. Rings werecontracted with 50 mM KCl to obtain the maximum contraction level fornormalization. Following a washout period of 30 min, the rings werepre-constricted with 10⁻⁶M phenylephrine and relaxed with a bolus doseof 10⁻⁷M acetylcholine to check the integrity of the endothelium.Following a second washout period of 30 min, rings were pre-constricteda second time with 10⁻⁶M phenylephrine and the contraction allowed tostabilize. A cumulative dose response of a Rho-kinase inhibitor wastested in a DMSO vehicle at a 1:1000 dilution using half log intervals.After each dose of inhibitor the response was allowed to stabilizebefore the addition of the next dose. Following the cumulative doseresponse with inhibitor, the tissues were washed 3× in PBS and allowedto equilibrate at resting tension. A second KCl contraction wasperformed as stated above to check the viability of the tissue.Following this, a second phenylephrine contraction and acetylcholinebolus dose were given as above to cheek for the integrity of theendothelium following inhibitor testing. The effect of the Rho-kinaseinhibitors were expressed as a percentage relaxation from thephenylephrine-induced contraction at each dose. The IC₅₀ for eachinhibitor was determined from the concentration that produced 50%relaxation from the phenylephrine-induced contraction. The data for eachinhibitor represents the mean from four different segments from fourdifferent rats.

Preferred compounds have an IC₅₀<10 μM in this assay.

Methods of Therapeutic Use

In accordance with the invention, there are provided novel methods ofusing the compounds of the formula (I). The compounds disclosed thereineffectively inhibit Rho kinase. The inhibition of Rho kinase is anattractive means for preventing and treating a variety of cardiovasculardiseases or conditions associated with Rho kinase activation. Thus, thecompounds are useful for the treatment of diseases and conditions asdescribed in the Background section, including the following conditionsand diseases; hypertension, atherosclerosis, restenosis, stroke,myocardial infarction, heart failure, coronary artery disease,peripheral artery disease, coronary vasospasm, cerebral vasospasm,ischemia/reperfusion injury, pulmonary hypertension, angina, erectiledysfunction, renal disease and organ failure. As disclosed in theBackground section, the compounds of the invention will also be usefulfor treating diseases or conditions associated with smooth muscle hyperreactivity or with activated Rho-kinase under other pathophysiologicalconditions. These diseases include but are not limited to asthma,glaucoma, cancer, Alzheimer's disease, multiple sclerosis, spinal cordinjury and neuropathic pain.

These disorders have been well characterized in man, but also exist witha similar etiology in other mammals, and can be treated bypharmaceutical compositions of the present invention.

For therapeutic use, the compounds of the invention may be administeredvia a pharmaceutical composition in any conventional pharmaceuticaldosage form in any conventional manner. Conventional dosage formstypically include a pharmaceutically acceptable carrier suitable to theparticular dosage form selected. Routes of administration include, butare not limited to, intravenously, intramuscularly, subcutaneously,intrasynovially, by infusion, sublingually, transdermally, orally,topically or by inhalation. The preferred modes of administration areoral and intravenous.

The compounds of this invention may be administered alone or incombination with adjuvants that enhance stability of the inhibitors,facilitate administration of pharmaceutical compositions containing themin certain embodiments, provide increased dissolution or dispersion,increase inhibitory activity, provide adjunct therapy, and the like,including other active ingredients. In one embodiment, for example,multiple compounds of the present invention can be administered.Advantageously, such combination therapies utilize lower dosages of theconventional therapeutics, thus avoiding possible toxicity and adverseside effects incurred when those agents are used as monotherapies.Compounds of the invention may be physically combined with theconventional therapeutics or other adjuvants into a singlepharmaceutical composition. Advantageously, the compounds may then beadministered together in a single dosage form. In some embodiments, thepharmaceutical compositions comprising such combinations of compoundscontain at least about 5%, but more preferably at least about 20%, of acompound of formula (I) (w/w) or a combination thereof. The optimumpercentage (w/w) of a compound of the invention may vary and is withinthe purview of those skilled in the art. Alternatively, the compounds ofthe present invention and the conventional therapeutics or otheradjuvants may be administered separately (either serially or inparallel). Separate dosing allows for greater flexibility in the dosingregime.

As mentioned above, dosage forms of the compounds of this invention mayinclude pharmaceutical acceptable carriers and adjuvants known to thoseof ordinary skill in the art and suitable to the dosage form. Thesecarriers and adjuvants include, for example, ion exchangers, alumina,aluminum stearate, lecithin, serum proteins, buffer substances, water,salts or electrolytes and cellulose-based substances. Preferred dosageforms include tablet, capsule, caplet, liquid, solution, suspension,emulsion, lozenges, syrup, reconstitutable powder, granule, suppositoryand transdermal patch. Dosage levels and requirements for the compoundsof the present invention may be selected by those of ordinary skill inthe art from available methods and techniques suitable for a particularpatient. In some embodiments, dosage levels range from about 1-1000mg/dose for a 70 kg patient. Although one dose per day may besufficient, up to 5 doses per day may be given. For oral doses, up to2000 mg/day may be required. As the skilled artisan will appreciate,lower or higher doses may be required depending on particular factors.For instance, specific dosage and treatment regimens will depend onfactors such as the patient's general health profile, the severity andcourse of the patient's disorder or disposition thereto, and thejudgment of the treating physician.

The invention claimed is:
 1. A compound selected from:1-(4-Chloro-phenyl)-cyclopentanecarboxylic acid(4-oxo-3,4-dihydro-quinazolin-7-yl)-amide;2-Benzylamino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-acetamide;1-Benzyl-piperidine-4-carboxylic acid(4-oxo-3,4-dihydro-quinazolin-7-yl)-amide; Pyrrolidine-2-carboxylic acid(4-oxo-3,4-dihydro-quinazolin-7-yl)-amide; 2-Amino-4-methyl-pentanoicacid (4-oxo-3,4-dihydro-quinazolin-7-yl)-amide;(R)-2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-3-phenyl-propionamide;(S)-2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-3-phenyl-propionamide;2-(Cyclohexylmethyl-amino)-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-acetamide;2-Methylamino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-phenyl-acetamide;2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-phenyl-acetamide;2-Cyclopropylamino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-phenyl-acetamide;(R)-2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-phenyl-acetamide;(R)-Pyrrolidine-2-carboxylic acid(4-oxo-3,4-dihydro-quinazolin-7-yl)-amide;(R)-2-Amino-3-methyl-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-butyramide;2-(Cyclopropylmethyl-amino)-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-acetamide;N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-(2-thiophen-2-yl-ethylamino)-acetamide;2-(Cyclohexyl-methyl-amino)-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-acetamide;N-(6-Chloro-4-oxo-3,4-dihydro-quinazolin-7-yl)-2-dimethylamino-2-phenyl-acetamide;N-(6-Chloro-4-oxo-3,4-dihydro-quinazolin-7-yl)-2-cyclopropylamino-2-phenyl-acetamide;2,5-Dimethyl-2H-pyrazole-3-carboxylic acid(4-oxo-3,4-dihydro-quinazolin-7-yl)-amide;(trans)-4-(3-Bromo-phenyl)-pyrrolidine-3-carboxylic acid(6-chloro-4-oxo-3,4-dihydro-quinazolin-7-yl)-amide;(R)—N-(6-Chloro-4-oxo-3,4-dihydro-quinazolin-7-yl)-2-(4-chloro-phenyl)-2-hydroxy-propionamide;(R)-2-(4-Chloro-phenyl)-2-hydroxy-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-propionamide;or a pharmaceutically acceptable salt thereof.
 2. A compositioncomprising the compound of claim
 1. 3. A pharmaceutical compositioncomprising the compound of claim 1 and a pharmaceutically acceptableexcipient or carrier.
 4. The compound of claim 1, wherein the compoundis selected from:(R)-2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-3-phenyl-propionamide;(S)-2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-3-phenyl-propionamide;(R)-2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-phenyl-acetamide;(R)-Pyrrolidine-2-carboxylic acid(4-oxo-3,4-dihydro-quinazolin-7-yl)-amide;(R)-2-Amino-3-methyl-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-butyramide;(trans)-4-(3-Bromo-phenyl)-pyrrolidine-3-carboxylic acid(6-chloro-4-oxo-3,4-dihydro-quinazolin-7-yl)-amide;(R)—N-(6-Chloro-4-oxo-3,4-dihydro-quinazolin-7-yl)-2-(4-chloro-phenyl)-2-hydroxy-propionamide;(R)-2-(4-Chloro-phenyl)-2-hydroxy-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-propionamide;or a pharmaceutically acceptable salt thereof.
 5. The compound of claim1, wherein the compound is 1-(4-Chloro-phenyl)-cyclopentanecarboxylicacid (4-oxo-3,4-dihydro-quinazolin-7-yl)-amide or a pharmaceuticallyacceptable salt thereof.
 6. The compound of claim 1, wherein thecompound is2-Benzylamino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-acetamide or apharmaceutically acceptable salt thereof.
 7. The compound of claim 1,wherein the compound is 1-Benzyl-piperidine-4-carboxylic acid(4-oxo-3,4-dihydro-quinazolin-7-yl)-amide or a pharmaceuticallyacceptable salt thereof.
 8. The compound of claim 1, wherein thecompound is Pyrrolidine-2-carboxylic acid(4-oxo-3,4-dihydro-quinazolin-7-yl)-amide or a pharmaceuticallyacceptable salt thereof.
 9. The compound of claim 1, wherein thecompound is 2-Amino-4-methyl-pentanoic acid(4-oxo-3,4-dihydro-quinazolin-7-yl)-amide or a pharmaceuticallyacceptable salt thereof.
 10. The compound of claim 1, wherein thecompound is2-(Cyclohexylmethyl-amino)-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-acetamideor a pharmaceutically acceptable salt thereof.
 11. The compound of claim1, wherein the compound is2-Methylamino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-phenyl-acetamideor a pharmaceutically acceptable salt thereof.
 12. The compound of claim1, wherein the compound is2-Amino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-phenyl-acetamide or apharmaceutically acceptable salt thereof.
 13. The compound of claim 1,wherein the compound is2-Cyclopropylamino-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-phenyl-acetamideor a pharmaceutically acceptable salt thereof.
 14. The compound of claim1, wherein the compound is2-(Cyclopropylmethyl-amino)-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-acetamideor a pharmaceutically acceptable salt thereof.
 15. The compound of claim1, wherein the compound isN-(4-oxo-3,4-dihydro-quinazolin-7-yl)-2-(2-thiophen-2-yl-ethylamino)-acetamideor a pharmaceutically acceptable salt thereof.
 16. The compound of claim1, wherein the compound is2-(Cyclohexyl-methyl-amino)-N-(4-oxo-3,4-dihydro-quinazolin-7-yl)-acetamideor a pharmaceutically acceptable salt thereof.
 17. The compound of claim1, wherein the compound isN-(6-Chloro-4-oxo-3,4-dihydro-quinazolin-7-yl)-2-dimethylamino-2-phenyl-acetamideor a pharmaceutically acceptable salt thereof.
 18. The compound of claim1, wherein the compound isN-(6-Chloro-4-oxo-3,4-dihydro-quinazolin-7-yl)-2-cyclopropylamino-2-phenyl-acetamideor a pharmaceutically acceptable salt thereof.
 19. The compound of claim1, wherein the compound is 2,5-Dimethyl-2H-pyrazole-3-carboxylic acid(4-oxo-3,4-dihydro-quinazolin-7-yl)-amide or a pharmaceuticallyacceptable salt thereof.